Registrant’s telephone number, including area code ~~(720) 442-7000~~(866) 668-2188

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes ☒ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☒☐ No ☐☒

The aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates on ~~December~~March 31, ~~2019~~2021 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately ~~$534,798,~~$1,578,929, computed by reference to the closing sales price of the shares of common stock on ~~December~~March 31, ~~2019,~~2021, which was ~~$0.0420.~~$0.124. The closing sales price and number of shares used to calculate the amount in the aforementioned sentence were as of March 31, 2021, and were not adjusted for the registrant’s 1 for 115 reverse stock split, which was effective on October 29, 2021.

The number of shares outstanding of the registrant’s common stock as of ~~October 6, 2020,~~May 31, 2022, was ~~127,333,060~~92,214,638 shares.

Information contained in this annual report on Form 10-K contains “forward-looking statements.” These forward-looking statements are contained principally in the sections titled “Business,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events, including, but not limited to: ~~our ability to consummate the Merger, as such term is defined below; the continued services of the Receiver, as such term is defined below;~~ our future financial performance; the continuation of historical trends; the sufficiency of our resources in funding our operations; our intention to engage in mergers and acquisitions; and our liquidity and capital needs. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include but are not limited to: the risks of limited management, labor and financial resources; our ability to establish and maintain adequate internal controls; our ability to develop and maintain a market in our securities; and our ability obtain financing, if and when needed, on terms that are acceptable. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

As used in this annual report on Form 10-K, ““HSMG,” “we”, “our”, “us” and the “Company” refer to Healthcare Solutions Management Group, Inc., a Delaware corporation and its subsidiaries unless the context requires otherwise.

~~Recent Developments~~Organizational History of the Company and Business Overview

~~Coronavirus (COVID-19)~~Healthcare Solutions Management Group, Inc., a Delaware corporation, and successor in interest to Verity Delaware Inc., a Delaware corporation which was previously a Nevada corporation named Verity Corp. was incorporated on April 11, 2006 in the state of Nevada under the name Infrared Systems, International.

On December 31, 2012, AquaLiv Technologies, Inc. (“ALTI”) and Verity Farms II, Inc. (“Verity Farms”), a South Dakota corporation, entered into a Share Exchange Agreement. Pursuant to the Share Exchange Agreement, ALTI acquired 100% of the authorized and issued shares of Verity Farms in exchange (the “Exchange”) for 4,850,000 shares of Series B Convertible Preferred Stock, par value $0.001 of ALTI, representing approximately 86% of the outstanding shares of ALTI, on a ~~fully-diluted~~fully diluted basis, assuming conversion into common stock. As a result of the Exchange and the other transactions contemplated thereunder, Verity Farms became a ~~wholly-owned~~wholly owned subsidiary of ALTI and ALTI acquired Verity Farms’ business operations. ALTI was formed under the laws of the State of Nevada on April 11, 2006 originally under the name of Infrared Systems International “ISI” as a ~~wholly-owned~~wholly owned subsidiary of China Sxan Biotech, Inc. (“CSBI”) (then known as Advance Technologies, Inc.) to pursue a narrowly defined business objective called infrared security systems.

On April 1, 2013, the Company changed its name from AquaLiv Technologies Inc. to Verity Corp. and our stock symbol changed to VRTY.

The Company was the parent of Verity Farms and Aistiva Corporation (“Aistiva”) (f/k/a AquaLiv, Inc.). Verity Farms was dedicated to providing consumers with safe, high-quality, and nutritious food sources through sustainable crop and livestock production. Aistiva previously released products in the industries of water treatment, skincare, and agriculture. Verity Farms was administratively dissolved in the State of South Dakota on May 4, 2018. ~~Aistivia~~Aistiva was administratively dissolved on April 9, 2015, in the State of Washington.

In February 2016, all of the Company’s officers and directors resigned, and the Company stopped substantially all operating activities. ~~Since~~At such time, ~~and currently,~~ the Company isbecame a “shell company,” as such term is defined in Rule 12b-2 under the ~~Securities~~ Exchange ~~Act~~Act.

On November 5, 2020, we changed our Fiscal Year End from June 30 to September 30. As a result of ~~1934,~~this change, we filed a Transition Report on Form 10-K with the SEC for the three-month transition period from June 30, 2020 to September 30, 2020 on January 20, 2021.

As a result of the consummation of the Merger, as ~~amended (the “Exchange Act”~~such term is defined below, on April 15, 2021, Healthcare Solutions Holdings, Inc., a Delaware corporation (“HSH”)., became our wholly owned subsidiary and the business of HSH became the business of the Company going forward. Accordingly, the Company ceased to be a shell company as of April 15, 2021.

On June 14, 2019, the Company entered into a Merger Agreement (the “Merger Agreement”) by and between the Company, Verity Merger Corp., a wholly-owned subsidiary of the Company and a Delaware corporation (the “Merger Sub”), and Healthcare Solutions Holdings, Inc., a Delaware corporation (“HSH”). Pursuant to the terms of the Merger Agreement, the parties agreed that Merger Sub would merge with and into HSH, with HSH being the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Merger”). The Merger closed on April 15, 2021 (the “Closing”), at which time Merger Sub merged with and into HSH with HSH being the surviving entity, and HSH became our wholly owned subsidiary. As a result of the consummation of the Merger, HSH became our wholly owned subsidiary and the business of HSH became the business of the Company going forward.

At the Closing of the Merger, Robert Stevens (the “Receiver”) appointed new officers and directors of the Company. As consideration for the services of the Receiver and his team, for acting as the court-appointed receiver for the Company and its predecessor and affiliated entities, and pursuant the Merger Agreement, as amended, in August of 2020, the Receiver and certain entities, as directed by the Receiver, were issued an aggregate total of 114,599,754 pre-reverse split shares of the Company’s common stock. At Closing, the aggregate Merger consideration paid to the holders of the HSH common was 1,145,997,555 pre-reverse split shares of the Company’s common stock constituting 90% of the issued and outstanding shares of Company common stock immediately following the Closing.

As a result of the consummation of the Merger, on April 15, 2021, HSH became our wholly owned subsidiary and the business of HSH became the business of the Company going forward. Accordingly, at the Closing, the Company ceased to be a shell company as of April 15, 2021.

In connection with the Merger, the Company appointed new officers and directors as described below.

On April 15, 2021, Justin Smith was appointed as the Company’s Interim Chief Executive Officer, Interim Chief Financial Officer and as the Executive Chairman and member of the Board of Directors of the Company.

On April 15, 2021, Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company.

On April 15, 2021, Jonathan Loutzenhiser was appointed as Executive Vice President of the Company and a member of the Board of Directors of the Company.

On April 15, 2021, Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company’s Chief Medical Officer.

On April 15, 2021, Dr. Sadeem Mahmood was appointed as the Company’s Chief of Surgery.

On April 15, 2021, Dr. Richard F. Wittock was appointed as the Company’s Vice President of Clinical Affairs.

On April 15, 2021, Dr. Richard Muckerman was appointed as the Company’s Vice President of Strategy and Business Development.

On April 15, 2021, Blake Moorman was appointed as the Company’s Vice President of Operations.

On April 15, 2021, Robert Stevens resigned from all of his positions with the Company. The foregoing resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

On May 16, 2016, pursuant to Case Number A16-733815-B, Nevada’s 8th Judicial District, Business Court, appointed Robert Stevens as receiver (the “Receiver”) for the Company. Creditors of the Company were required to provide claims in writing under oath on or before November 3, 2016, or they would be barred under Nevada Revised Statute §78.675.

Since May 16, 2016, through the date of ~~this Annual Report,~~the Merger, the Company ~~has been~~was operating under the direction of the Receiver.

On March ~~22,~~5, 2018, the District Court in Clark County, Nevada approved a plan of reorganization ~~that involved authorizing~~for the ~~cancellation~~Company and the discharge of ~~all preferred shares~~the Receiver upon completion of his duties under the court order. Upon the Closing of the Merger, the reorganization of the Company the cancellation of certain insider shares, a reverse stock split up to a maximum of 200-1, and a reorganization that would place the liquidation of the Company’s assets under a liquidating trustee while maintaining the public, purchasers for value with equitydescribed in the ~~surviving entity. Once~~court order was completed and, as a result and pursuant to the ~~reorganization is completed~~court order dated March 5, 2018, the Receiver ~~will be discharged.~~was automatically discharged and the receivership was automatically terminated such that no further action was needed by the Receiver or the Company in connection with the receivership, and such that Company was no longer in receivership.

On March 15, 2019, Healthcare Solutions Management Group, Inc. was incorporated in the State of Delaware. Verity Delaware, Inc. was incorporated in the State of Delaware on March 11, 2019. Verity Merger Corp. was incorporated in the State of Delaware on March 15, 2019. On March 11, 2019, pursuant to an Agreement and Plan of Conversion, the Company, then a Nevada corporation named Verity Corp., converted into, and became Verity Delaware, Inc., a Delaware corporation in Delaware and on May 30, 2019, the conversion was completed in Nevada. As a result of the foregoing, Verity Corp. a Nevada corporation converted into and became Verity Delaware, Inc., a Delaware corporation. On May 8, 2019, pursuant to a Plan of Merger, Verity Delaware, Inc. was merged with and into Verity Merger Corp., with Verity Merger Corp. surviving, and with Healthcare Solutions Management Group, Inc. becoming a successor in interest to Verity Delaware Inc. and the parent company of Verity Merger Corp.

On November 5, 2020, the Company’s court appointed receiver, acting under judicial order on behalf of the Board of Directors of the Company, in accordance with the Company’s Bylaws, acted by written consent to change the Company’s Fiscal Year End from June 30 to September 30. As a result of this change, we filed a Transition Report on Form 10-K for the three-month transition period from June 30, 2020 to September 30, 2020 on January 20, 2021.

On March 11, 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic which continued to spread throughout the U.S. and the globe. In addition to the devastating effects on human life, the pandemic is continuing to have a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. COVID-19 has already hindered or slowed many of HSH’s businesses, including but not limited to our growth and growth strategies, developments in the marketplace for products, therapies and services, financial results, research and development strategy, regulatory approvals, and competitive strengths. The direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition, continues today, but HSH has thus far weathered the pandemic storm and continues to seek to improve our level of service and patient care. The extent of the ultimate impact of the pandemic on the Company’s operational and financial performance will depend on various developments, including the duration and continued spread of the outbreak, which cannot be reasonably predicted at this time. Accordingly, while management reasonably expects the COVID-19 outbreak to negatively impact the Company, the related consequences and duration are highly uncertain and cannot be predicted at this time.

We operate through our wholly owned subsidiary HSH. HSH is an integrated healthcare company which strives to provide vital services and a high-quality of care for patients over the course of their lifetime. HSH was organized with the goal of becoming an advanced, national healthcare system in the United States, providing clinicians with state-of-the-art diagnostic and therapeutic tools, and providing patients with greater access to a higher level of care in local communities that we believe have historically been underserved by the medical industry. HSH currently conducts its operations directly through HSH, and also through its wholly owned subsidiaries within the medical industry, seeking to serve the needs of patients’ and physicians alike.

HSH currently has the following wholly owned operating subsidiaries in the state of Delaware through which it operates its business:

To date, the majority of HSH’s revenues have been generated through resales and marketing of medical products which HSH has done directly at the HSH level using the trade name HSHMS. HSH has formed HSHMS in the state of Delaware, and it plans to conduct all such resale and marketing activities through HSHMS. HSH has also generated revenues through providing consulting services to Managed Service Organizations (“MSOs”).

The Company has recently sought to expand its business and service offering capabilities and has shifted its focus away from medical product sales towards providing services to patients through its planned surgical and urgent care and internal medicine health facilities which it plans to conduct through ACM and HSHS. The Company expects that, going forward, revenues from its ownership interests in these facilities will comprise the majority of the Company’s revenues as the Company focuses more on those areas and less on medical products. The specific products and/or services intended to be provided by each of HSH’s operating subsidiaries are described in detail below.

HSH has provided consulting services to Managed Service Organizations (“MSOs”) and as further described below, HSH plans to establish another wholly-owned operating subsidiary to provide MSOs with both business management, development, and operational assistance. Additionally, HSH intends to become a comprehensive medical incubator and innovation center, dedicated to accelerating development, building businesses, and improving patient outcomes

Since Healthcare Solutions Management Group, Inc. became the successor in interest to Verity Delaware Inc. a Delaware corporation which was previously a Nevada corporation named Verity Corp., the Company’s current name isbecame Healthcare Solutions Management Group, Inc. ~~The~~

On September 13, 2021, the Board of Directors (the “Board”) of the “Company approved (i) a 1 for 115 Reverse Stock Split of the Company’s common stock with any fractional shares of common stock resulting therefrom being rounded up to the nearest whole share of common stock (the “Reverse Stock Split”) and (ii) a voluntary change in the Company’s stock symbol from “VRTY” to a symbol selected by the Company’s officers (the “Symbol Change” and together with the Reverse Stock Split, referred to herein together as the “Corporate Actions”). On the same date, 52.42 % of the Company’s shareholders also approved the Corporate Actions. On September 15, 2021, the Company ~~plans~~filed a Certificate of Amendment to ~~submit~~its Amended and Restated Certificate of Incorporation (the “Certificate”) with the Delaware Secretary of State for the Reverse Stock Split, with an ~~Issuer Company-Related Action Notification Form (the “Name Change”) to~~effective date of the later of (i) September 29, 2021, or (ii) on a date that the Reverse Stock Split, is announced by Financial Industry Regulatory Authority (“FINRA”) ~~to request that~~.

The Company submitted an Issuer Company Related Action Notification regarding the ~~Company’s~~Corporate Actions, as well as its prior name ~~be updated~~change to its current name to FINRA on September 15, 2021 (the name change together with the Reverse Stock Split and Symbol Change are referred to ~~change~~herein together as the “Corporate Actions”). The Company was then notified by FINRA that the market effective date for the Corporate Actions was October 29, 2021. The new trading symbol for the Company’s ~~trading~~common stock as of October 29, 2021, was “VRTYD” and effective as of November 26, 2021 the symbol ~~accordingly.~~changed to “HSMD.” Further, the Company’s common stock now has the following CUSIP number: 42226Y 105. The ~~Company has not yet submitted the Name Change to FINRA and there can be no assurance that FINRA will process the Name Change as planned, or at all.~~reverse stock split was effective on October 29, 2021.

~~In February 2016, all~~On September 14, 2021, the Company’s wholly owned subsidiary, HSH terminated a consulting agreement (the “Consulting Agreement”) dated October 1, 2018, between HSH and Tarun Jolly (the “Consultant”), pursuant to Section 20(e) of the ~~Company’s officers and directors resigned, and~~Consulting Agreement, which permits HSH to terminate the Consulting Agreement any time without cause, with the termination to be effective as of September 15, 2021. Pursuant to the Consulting Agreement, the Company ~~stopped substantially~~had engaged the Consultant to provide general business, advisory and transaction, support and consulting services to HSH in exchange for warrants to purchase shares of HSH upon the occurrence of certain milestones none of which were ever achieved.

On September 14, 2021, HSH terminated a Consulting Services Agreement by and between Flex Surgical Management LLC and Matt Thibaut, an individual and HSH dated September 1, 2020 (the “Agreement”) pursuant to Section 17(e) of the Agreement and all ~~operating activities. Since such time,~~other terms and ~~currently,~~conditions of the Agreement. Termination will be effective as of September 16, 2021, in accordance with the terms and provisions of the Agreement.

On September 14, 2021, HSH terminated a Field Representative Offer of Employment by and between Stephen Fertig, an individual and HSH dated August 21, 2019 (the “Offer”) pursuant to Section 7 of the Offer and all other terms and conditions of the Offer. Termination will be effective as of September 16, 2021, in accordance with the terms and provisions of the Offer.

On September 14, 2021, HSH terminated an Independent Contractor Agreement by and between John Keeling, Jr., an individual and HSH dated October 22, 2018 (the “Agreement”) pursuant to Section 4(4.2) of the Agreement and all other terms and conditions of the Agreement. Termination will be effective as of September 15, 2021, in accordance with the terms and provisions of the Agreement.

On September 14, 2021, HSH terminated a Consulting Services Agreement by and between BBCV Group, LLC and HSH dated October 30, 2019 (the “Agreement”) pursuant to Section 6(a) of the Agreement and all other terms and conditions of the Agreement. Termination will be effective as of September 30, 2021, in accordance with the terms and provisions of the Agreement.

On November 26, 2021, the Company and HSH and HSH’s wholly owned subsidiary HSH Surgical, Inc. (“HSHS”) entered into an Ambulatory Surgery Center Development Agreement (the “Agreement”) with Jameson, LLC DBA American Development Partners, a Tennessee limited liability company (together with its subsidiaries, related parties, successors-in-interests, and affiliates, the “Developer”). The term of the Agreement is ~~a “shell company,~~ten (10) years from November 26, 2021. Pursuant to the Agreement, the Developer agreed to use commercially reasonable efforts to present HSHS with “Qualified Projects,” as such term is defined in ~~Rule 12b-2 under~~ the ~~Exchange Act. Since May 16, 2016, through~~Agreement. During the ~~date~~term of ~~this Annual Report,~~the Agreement, the Developer agreed to present HSHS with ten (10) Qualified Projects per year, HSHS however is not required to accept a Qualified Project. HSHS agreed to enter into one hundred (100) Lease Agreements (the “Tenant Commitment”) with an option for twenty-five (25) additional units with anticipated development costs to be approximately fourteen million dollars ($14,000,000) a unit (actual costs will vary based on individual projects) for a total initial commitment of approximately one billion four hundred million dollars ($1,400,000,000) with an option for an additional three hundred and fifty million dollars ($350,000,000); provided that each Lease Agreement relates to a Qualified Project. Pursuant to the Agreement, the Developer has the exclusive rights to develop single tenant HSH Surgical Ambulatory Surgery Center units on a nationwide basis for HSHS.

On November 26, 2021, the Company, ~~has been operating under~~HSH and HSH’s wholly owned subsidiary Advance Care Medical Holdings, Inc. (“ACM”) entered into an Urgent Care Center Development Agreement (the “UC Agreement”) with Jameson, LLC DBA American Development Partners, a Tennessee limited liability company (together with its subsidiaries, related parties, successors-in-interests, and affiliates, the ~~direction~~“Developer”). The term of the ~~Receiver.~~

The Company has no operations at this time, and currently does not have any principal products or services, customers or intellectual property. As the Company has no current operations, it also currentlyUC Agreement is ~~not subject to any competitive business conditions. Further, the Company is not subject to any government approvals at this time, other than those related~~ten (10) years from November 26, 2021. Pursuant to the ~~receivership and those applicable~~UC Agreement, the Developer agreed to ~~it as a “shell company,~~use commercially reasonable efforts to present ACM with “Qualified Projects,” as such term is defined in ~~Rule 12b-2 under~~ the ~~Exchange Act.~~UC Agreement. During the term of the UC Agreement, the Developer agreed to present ACM with seventy-five (75) Qualified Projects per year, however ACM is not required to accept a Qualified Project. ACM agreed to enter into five hundred (500) Lease Agreements (the “Tenant Commitment”) with an option for two hundred (200) additional units with anticipated development costs to be approximately four million five hundred thousand dollars ($4,500,000) a unit (actual costs will vary based on individual projects) or a total initial commitment of approximately two billion two hundred and fifty million dollars ($2,250,000,000.00) with an option for an additional nine hundred million dollars ($900,000,000); provided that each Lease Agreement relates to a Qualified Project. The developer has the exclusive rights to develop single tenant Advance Care Medical Urgent and Comprehensive Care Center units on a nationwide basis for ACM.

The entry into the Agreement and the UC Agreement, triggered the issuance, on December 31, 2021 by the Company of 81,000,000 shares of its common stock to the following parties in the following amounts (the “Shares”).

As of October 6, 2020, we have no part-time or full-time employees (excluding the Receiver and his staff). Since May 16, 2016, through the date of this Annual Report, the Company has been operating under the direction of the Receiver.

	·	A management consulting agreement with Black Label Services, Inc., dated July 15, 2018: 22,000,000 shares of common stock.

	·	A management consulting agreement with Jackson Hole Medical Advisors, Inc., dated July 15, 2018: 22,000,000 shares of common stock.

	·	An employment agreement with Jonathan Loutzenhiser, dated July 15, 2018: 22,000,000 shares of common stock.

	·	A consulting services agreement with 168 Capital, Inc., dated October 1, 2018: 9,000,000 shares of common stock.

	·	A consulting services agreement with Alpha Properties LLC., dated October 1, 2018: 3,000,000 shares of common stock.

	·	A consulting services agreement with Stin Marketing Group LLC., dated October 1, 2018: 3,000,000 shares of common stock.

~~Merger Agreement with Healthcare Solutions Holdings,~~Advance Care Medical Inc.

~~On June 14, 2019, the Company (the successor in interest to Verity Delaware~~HSH’s wholly owned subsidiary Advance Care Medical Holdings, Inc., (“ACM”) is a Delaware corporation ~~which was previously~~that seeks to be a ~~Nevada corporation named Verity Corp.)~~direct provider of urgent care and internal medicine services, and all comprehensive care provided by HSH is run through ACM. ACM aims to bridge the gap between urgent family care and the traditional hospital system. Through ACM, our mission is to focus on inadequately served communities and provide them more convenient quality healthcare. Our newly constructed facilities will seek to provide the highest standards of safety, comfort, and convenience for the best patient experience.

ACM plans to set up comprehensive care services that aim to combine both internal medicine practices with urgent care at numerous locations.

Each of the facilities at these locations are planned to be leased and it’s planned that ACM will do the build out of the medical premises at these facilities. As described above, on November 26, 2021, the Company, HSH and ACM entered into an Urgent Care Center Development Agreement with Jameson, LLC DBA American Development Partners, a ~~Merger Agreement (the “Merger Agreement”) by~~Tennessee limited liability company.

It is planned that these facilities will be equipped with state-of the-art equipment and ~~between the Company, Verity Merger Corp.,~~will be fully-staffed with Primary Care Physicians, Urgent Care Physicians and/or support staff to provide medical services. Many of these facilities are panned to be located in traditionally under-served rural communities, which we have intentionally targeted to help serve what we believe is a ~~wholly-owned subsidiary~~population in need of ~~the Company (the “Merger Sub”), and Healthcare Solutions Holdings, Inc. (“HSH”). Pursuant~~better medical services.

Medical services planned to be provided at these facilities will include, but are not limited to, the terms of the Merger Agreement, the parties agreed that Merger Sub would merge with and into HSH, with HSH being the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Merger”).following:

It is planned that ACM will bill both private and government insurance for the services provided to patients at these facilities. It is also planned that ACM will accept direct payment for the above services it will provide from patients.

To date HSH has completed construction of facilities in Georgia, Illinois, and Tennessee, and HSH is in the process of completing medical equipment installations at these locations and hiring and training of staff. HSH is in the process of completing construction of facilities in Illinois, Tennessee, Georgia and Utah. The ~~closing~~locations are set up under the following names, and the locations which are staffed, trained and ready to see patients are noted as such below:

Advance Care Medical Naperville IL - I, Inc. – this location is staffed, trained and ready to see patients

Advance Care Medical Romeoville IL- I, Inc.- this location is staffed, trained and ready to see patients

Advance Care Medical Clarkesville TN, Inc. - this location is staffed, trained and ready to see patients

Advance Care Medical Columbia TN, Inc. - this location is staffed, trained and ready to see patients

HSH’s wholly owned subsidiary HSH Surgical, Inc., (HSHS) is a Delaware corporation. HSHS is a physician-centric development and management company of multi-specialty, cardiology focused, ambulatory surgery centers. HSHS seeks to strive to become an industry-leading ambulatory surgery center (“ASC”) management and development company focused on partnering with physicians and employees to create an outstanding patient experience. HSHS seeks to partner with physicians to develop, design, build, credential, and then manage ASCs for, and with, their physician partners. HSHS also seeks to work with physicians in a joint-venture relationship with local hospitals or health systems, if we determine that such a relationship is in the best interest of the ~~Merger is planned to take place on~~physicians and the ~~third business day following~~ASC.

We believe that physician partners are the ~~satisfaction or waiver (by the party for whose benefit the condition exists)~~lifeline of any ASC, and they should retain control of the ~~closing conditions in~~facility while HSHS can focus on adding value by managing the ~~Merger Agreement or~~business side while allowing the physician partners to focus on patient care. As such, ~~other date and at such other time and place as the parties agree in writing.~~

Upon the effective time of the Merger, (i) HSH’s certificate of incorporation will be the certificate of incorporation of the surviving company, (ii) HSH’s bylaws will be the bylaws of the surviving company, (iii) HSH’s directors immediately prior to the effectiveness of the Merger will be the directors of the surviving company and (iv) HSH’s officers immediately prior to the effectiveness of the Merger will be the officers of the surviving company.

~~At the closing of the Merger,~~ it is planned, that ~~the Receiver~~HSHS, will ~~elect Justin Smith, Jonathan Loutzenhiser and Dr. Charles Balaban as members~~provide 30% of the ~~Company’s board~~funding for an initial ASC project, and the physicians will provide 70%, resulting in HSHS being a minority 30% owner of ~~directors,~~each ASC that it will manage and ~~then resign.~~develops in partnership with physicians. It is planned that HSHS will only seek to partner with top-quality, board-certified surgeons to provide the surgical services at these ASC facilities.

The aggregate Merger consideration to be paid to the holders of the HSH common stock at the effective time of the Merger will be an aggregate number of shares of the Company’s common stock constituting 90% of the issued and outstanding shares of Company common stock immediately following the closing.

At the effective time of the Merger, each share of HSH common stock issued and outstanding immediately prior to the effective time (other than shares canceled as provided in the Merger Agreement, if any), will be converted into shares of Company common stock, at an exchange ratio as required to cause the number of shares of Company common stock issued to the holders of the HSH common stock to be 90% of the issued and outstanding shares of the Company common stock immediately following the closing, which is currently expected to result in an exchange ratio of 127.33306 shares of Company common stock per share of HSH common stock (as ultimately so determined, the “Exchange Ratio”), with any fractional shares of Company common stock being rounded to the nearest whole share of Company common stock. The Exchange Ratio will be finally determined by the parties to the Merger Agreement prior to the closing.

As consideration for the services of Robert Stevens and his team, for acting as the court-appointed receiver for the Company and its predecessor and affiliated entities, and pursuant the Merger Agreement, the Company agreed to issue to certain parties as directed by Mr. Stevens, shares of Company common stock equal to 90% of the issued and outstanding shares of Company common stock prior to the closing, which will therefore constitute 9% of the issued and outstanding shares of Company common stock immediately following the closing (the “Receiver Shares”).

The completion of the Merger is subject to certain customary closing conditions, including that HSH will have provided to the Company, HSH’s audited and unaudited financial statements as required to be included in the Company’s filings with the Securities and Exchange Commission.

~~The Merger Agreement is not subject to a financing condition. The parties have made customary representations, warranties, and covenants in the Merger Agreement. The Merger Agreement~~HSHS also contains a customary “no-shop” covenant prohibiting the Company from soliciting proposals for alternative acquisition or providing information or participating in any discussions in connection with any such proposals.

The Merger Agreement contains certain termination rights that may be exercised by the Company or HSH, as applicable, including in the event that (i) both parties agree by mutual written consent to terminate the Merger Agreement, (ii) the Merger is not consummated by September 30, 2020 (as set forth in the “Amendment” discussed below), or (iii) any law or order permanently restraining, enjoining or otherwise prohibiting consummation of the Merger having become final and non-appealable.

~~The Merger is intended~~aims to be a ~~reorganization within the meaning~~direct provider of ~~Section 368(a)~~ambulatory surgery services, and all of the ~~Internal Revenue Code~~ambulatory and surgery business of ~~1986, as amended (the “Code”), and the Merger Agreement is intended to be~~HSH are run through this subsidiary. Our planned ASCs are comprised of a “plan of reorganization” within the meaning of the regulations promulgated under Section 368(a) of the Code and for the purpose of qualifying as a tax-free transaction for federal income tax purposes.

It is planned that HSHS, will have a 30% ownership interest in numerous locations set up for our planned ambulatory surgery services, the first of which SARC by HSH ASC Pine Bluff has opened and is performing procedures in Pine Bluff, AR. The remaining ownership of these entities is planned to ~~reasonably cooperate~~be held by physician providers.

We plan that a wide array of surgical services will be provided through these ASC’s, which are planned to ~~terminate~~include, but are not limited to, the ~~engagement~~following:

For each of these services, it is planned that HSHS, will bill accept both private and government insurances, and accept direct payments from patients.

To date HSHS has completed construction of a state of the ~~Company’s prior registered agent~~art Ambulatory Surgery Center in ~~Nevada, with~~Pine Bluff, Arkansas, and HSHS is in the ~~costs related thereto~~process of completing construction in Utah and Texas. The locations are set up under the following names:

To date, the majority of HSH’s revenues have been generated through resales and marketing of medical products which HSH has done directly at the HSH level using the trade name HSHMS. HSH does not produce or manufacture its own products or services – rather, it is a third-party reseller of medical products and services, whereby medical companies grant HSH a right, which can be exclusive or non-exclusive, to market, distribute and sell such company’s medical products and services to physician customers in certain regions. In exchange, HSH receives a mark-up, which is generally twenty percent (20%) of the gross sales it makes from reselling those products and services.

HSH currently sells products across the U.S. in over 18 states. HSH’s customers are physicians, to which it markets and sells medical equipment, medical devices, laboratory services, and pharmacy services, as well as other services directly to its physician customers.

HSHMS was formed in the state of Delaware, and HSH plans to conduct all such resale and marketing activities through HSHMS. HSHMS is intended to focus on sales and marketing of medical products and services to doctors. All third-party products and services that will be resold by HSH are planned to be ~~paid~~provided through this subsidiary.

HSH, now offers, and HSHMS, is planned to offer products and services in the following categories directly to physicians:

HSH has built strong relationships throughout the healthcare field over several years, and our sales team which has decades of medical practice relationships has helped our rolodex continue to grow through networking and current client referrals. HSH acquires its medical equipment and services by ~~HSH. Further, pursuant to~~procuring and vetting various leading medical technology/manufacturing companies across the ~~Amendment,~~country based on availability, pricing, and overall service. The products and services are typically installed by the ~~Company agreed to issue the Receiver Shares~~different vendors and serviced as required by the ~~Merger Agreement~~manufacturer(s). If these products and services require physical operation, HSH recruits the appropriate personnel to do so.

As noted above, the foregoing operations are intended to be conducted through HSHMS.

HSH has generated revenues through providing consulting services to Managed Service Organizations (“MSOs”). HSH has provided consulting services to Managed Service Organizations (“MSOs”). HSH intends to establish another wholly-owned operating subsidiary to provide Managed Service Organizations (MSOs) with both business management, development, and operational assistance. MSO physician groups operate under a single tax ID to optimize expenses against utilization of services to create a more efficient physician practice. In the past, HSH has directly provided such consulting services to MSO’s. In the future HSH seeks to provide these services solely through its operating subsidiaries.

The services HSH intends to offer in ~~book entry within 10 days of August 25, 2020. The Receiver Shares were issued on August 27, 2020 and consisted of a total of 114,599,754 shares of Company common stock.~~through this subsidiary include:

~~Further,~~A core focus of HSH’s MSO practice will be to provide consultation on the development and management of 100% MSO owned services in the ancillary space and provide operational support for them.

An MSO can be a gateway for providers to apply a population health lens to their practice or network with a focus on quality and outcomes, ultimately enabling the practice to better control overall the total cost of care. MSOs, administrative services organizations (ASOs), care management organizations (CMOs), population health services organizations (PHSOs) and the functions they provide, come in many shapes and sizes. The governance structure and functionality of an MSO is unique to the health system, independent practice association (IPA), ACO or health plan it is designed to serve. A provider taking risk can design or outsource an MSO for a single function/service or many functions/services depending on their needs. Many health systems are balancing the MSO type needs of a wholly owned or joint venture health plan, one or more ACOs and one or more IPAs. As a result, health systems and provider organizations are grappling with decisions about which functions they can realistically provide and how they can organize themselves to deliver these functions in a cost-effective way that allows them to capture and effectively manage as much of the premium dollar as possible.

HSH intends to work in collaboration with clients to help them understand the value of MSO infrastructure as they consider opportunities to manage risk, improve financial and clinical performance and meet the needs of all members. We plan that our subsidiaries will help clients to understand the scope of MSO service and capabilities, assess existing MSO services and capabilities and recommend solutions to optimize performance, align with market drivers, and achieve both short and long-term member management goals. We also intend to assist providers to establish their own MSO entities, including build/buy decision support, to help best control and manage risk. We will custom tailor consulting fee arrangements to the economic capabilities of our clients with both hourly payment charge options, total gross project billing, or monthly and annual retainer services.

HSH intends to be a comprehensive medical incubator and innovation center, with a team dedicated to accelerating development, building businesses, and improving patient outcomes. HSH’s team to date has worked with clinician innovators, university tech transfer offices, and academic researchers to design, engineer, prototype, and facilitate commercialization of a broad range of innovative medical products and companies.

HSH’s core management team of physicians, clinicians, and M&A subject matter experts are intended to collaborate closely with new product development teams, MedTech entrepreneurs, and medical providers seeking to accelerate time to market while reducing costs.

HSH plans to work to diligently to identify High Growth Healthcare Companies (HGHCs) that are candidates for the public market. In this capacity, we seek to:

We intend to perform these operations at the HSH level, and believe that our expertise in this field will prove valuable in our ability to identify and assist promising companies in this space.

On July 15, 2018, HSH entered into a consulting agreement (the “Consulting Agreement”) with DMM Advisors, Inc. (the “Consultant”) pursuant to which HSH engaged the ~~Amendment,~~Consultant to provide general business, management, advisory and support consulting services to HSH. As compensation under the Consulting Agreement, HSH agreed to pay the ~~costs~~Consultant a non-refundable retainer of $100,000 per month and ~~expenses~~agreed to pay the Consultant a monthly automobile allowance of $2,500. The Consulting Agreement also provides that the ~~Company resulting~~Consultant will be eligible to receive awards from ~~the Company’s engagement of professional service providers, including, but not limited~~HSH under their stock and bonus plans once such plans are created and also eligible to ~~those of the transfer agent, legal counsel and auditors, until the earlier of the closing or the termination of the Merger Agreement.~~

~~Further,~~be covered by liability insurance once HSH acquires same. Additionally, pursuant to the ~~Amendment,~~Consulting Agreement, the ~~parties acknowledged~~Consultant is eligible to receive a bonus in cash and in shares of HSH, as well as warrants to purchase shares of HSH, upon meeting certain milestones. The term of the Consulting Agreement is for a period of three (3) years and will be automatically renewed for one (1) year terms unless terminated. The Consulting Agreement can be terminated by HSH for “cause” as such term is defined in the Consulting Agreement and the Consultant can terminate the Consulting Agreement at any time for any reason by giving HSH 30 days’ notice. HSH can also terminate the Consulting Agreement without cause at any time.

On October 1, 2018, HSH entered into a consulting agreement (the “Consulting Agreement”) with Stin Marketing Group, LLC (the “Consultant”) pursuant to which HSH engaged the Consultant to provide general business, advisory and transaction, support and consulting services to HSH. As compensation under the Consulting Agreement, HSH agreed to pay the Consultant by issuing warrants to purchase shares of HSH upon the occurrence of certain milestones. The term of the Consulting Agreement is for two (2) years and renews automatically for one (1) year terms unless terminated. The Consulting Agreement can be terminated by HSH for “cause” as such term is defined in the Consulting Agreement and the Consultant can terminate the Consulting Agreement at any time for any reason by giving HSH 30 days’ notice. HSH can also terminate the Consulting Agreement without cause at any time.

On October 1, 2018, HSH entered into a consulting agreement (the “Consulting Agreement”) with 168 Capital, Inc. (the “Consultant”) pursuant to which HSH engaged the Consultant to provide general business, advisory and transaction, support and consulting services to HSH. As compensation under the Consulting Agreement, HSH agreed to pay the Consultant by issuing warrants to purchase shares of HSH upon the occurrence of certain milestones. The term of the Consulting Agreement is for two (2) years and renews automatically for one (1) year terms unless terminated. The Consulting Agreement can be terminated by HSH for “cause” as such term is defined in the Consulting Agreement and the Consultant can terminate the Consulting Agreement at any time for any reason by giving HSH 30 days’ notice. HSH can also terminate the Consulting Agreement without cause at any time.

On October 1, 2018, HSH entered into a consulting agreement (the “Consulting Agreement”) with Alpha Properties, LLC (the “Consultant”) pursuant to which HSH engaged the Consultant to provide general business, advisory and transaction, support and consulting services to HSH. As compensation under the Consulting Agreement, HSH agreed to pay the Consultant by issuing warrants to purchase shares of HSH upon the occurrence of certain milestones. The term of the Consulting Agreement is for two (2) years and renews automatically for one (1) year terms unless terminated. The Consulting Agreement can be terminated by HSH for “cause” as such term is defined in the Consulting Agreement and the Consultant can terminate the Consulting Agreement at any time for any reason by giving HSH 30 days’ notice. HSH can also terminate the Consulting Agreement without cause at any time.

On July 15, 2018, HSH entered into a consulting agreement (the “Consulting Agreement”) with Black Label Services, Inc. (the “Consultant”) pursuant to which HSH engaged the Consultant to provide general business, management, advisory and support consulting services to HSH. As compensation under the Consulting Agreement, HSH agreed to pay the Consultant a non-refundable retainer of $100,000 per month and agreed to pay the Consultant a monthly automobile allowance of $2,500. The Consulting Agreement also provides that the ~~Company~~Consultant will be eligible to receive awards from HSH under their stock and bonus plans once such plans are created and also eligible to be covered by liability insurance once HSH ~~are represented by~~acquires same. Additionally, pursuant to the ~~same legal counsel~~Consulting Agreement, the Consultant is eligible to receive a bonus in cash and ~~that counsel has advised each~~in shares of HSH, as well as warrants to purchase shares of HSH, upon meeting certain milestones. The term of the ~~parties~~Consulting Agreement is for a period of five (5) years and will be automatically renewed for one (1) year terms unless terminated. The Consulting Agreement can be terminated by HSH for “cause” as such term is defined in the Consulting Agreement and the Consultant can terminate the Consulting Agreement at any time for any reason by giving HSH 30 days’ notice. HSH can also terminate the Consulting Agreement without cause at any time.

HSH, works with suppliers and manufacturing companies on a reseller basis. HSH utilizes its physician network to ~~retain separate counsel~~review, vet-out, and help implement new diagnostic and therapeutic treatments and devices in other physician offices. HSH is compensated by its suppliers and manufactures for the products and services that are resold through the HSH network. HSH has formed HSHMS to ~~review~~conduct these operations in the future.

For ACM and HSHS, “supply” will be in the form of quality medical physicians and healthcare workers that we recruit from various sources.

HSH is not materially reliant on any one supplier for its products or service offerings.

HSH utilizes third-party marketing agencies for its sales and marketing activities.

On October 6, 2020, HSH entered into a Master Services Agreement (the “MSA”) with GrowthMed, Inc., a California corporation (“GrowthMed”). Pursuant to the MSA, GrowthMed agreed to provide HSH with custom responsive design and initial website setup and creation services as well as maintenance services for same, webhosting, advertising, email hosting and other related services (referred to herein as the “Services”). Pursuant to the MSA, HSH agreed to compensate GrowthMed with a total build fee of $30,000, including a $15,000 build fee deposit and a maintenance fee of $3,500 for the Services. The minimum term of the MSA is for 12 months (the “Minimum Term”) at which time the MSA will automatically renew for subsequent six (6) month periods until terminated by either party. Prior to the conclusion of the Minimum Term, the MSA can be terminated by either party, for any reason or no reason, upon 3 months written notice to the other party. After the conclusion of the Minimum Term, the MSA can be terminated by either party upon 30 days’ notice to the other party, with such notice required to be made at least 30 days prior to the next upcoming renewal date.

On April 12, 2021, HSH terminated the MSA with GrowthMed, Inc. in accordance with the terms of the ~~Merger Agreement~~MSA, and the ~~Amendment,~~Termination was effective immediately pursuant to terms and ~~that each party waived such right and waived any related conflicts of interests and confirmed that the parties have previously negotiated the material terms~~provisions of the ~~Merger Agreement~~MSA.

HSH has engaged Hearst Media Services - a full-service marketing/communications and technology firm that has been delivering targeted multi-channel programs and services for more than 100 years – to assist the ~~Amendment. Further, pursuant to the Amendment, the prior notice person~~Company with its digital marketing strategy. HSH entered into an agreement (the “Agreement”) with Hearst Media Services on February 11, 2021 for the ~~Company was removed.~~

~~Other than~~foregoing services. There is a $13,000 set up fee and a $600 monthly rate payable by HSH to Hearst Media Services under the ~~foregoing, no other material changes were made to~~Agreement as compensation for the ~~Merger Agreement in the Amendment.~~

services thereunder. The foregoing description of the ~~Merger~~ Agreement ~~and the Amendment, and the transactions contemplated thereby~~ does not purport to be complete and is qualified in its entirety by the ~~Merger~~full text of the Agreement, ~~and the Amendment, copies~~a copy of which ~~are~~is filed as Exhibit ~~2.1~~10.9 hereto and ~~2.2, respectively,~~is incorporated by reference herein.

HSH believes that Hearst Media Services can help raise the Company’s profile and create increased awareness and greater visibility of HSH in the medical industry.

We have experienced, and expect to continue to experience, intense competition from a number of companies. Our primary competitors are HCA Healthcare, Texas Health Resources, UT Southwestern Medical Center, Tenet, DaVita and VCA. HSH is seeking to create a paradigm shift in the healthcare industry by creating a new form of national healthcare complex that is highly efficient, provides greater access for all patients and drives superior patient outcomes. We believe that this ~~Annual Report~~paradigm shift will improve the financial sustainability of the American healthcare system and lead to a higher quality of care.

However, many of our competitors and potential competitors have significantly greater financial, technological, and other resources and name recognition than we do and more established distribution networks and relationships with healthcare providers. As a result, many of these companies may respond more quickly to new or emerging technologies and standards and changes in customer requirements. These companies may be able to invest more resources in research and development, strategic acquisitions, sales and marketing, patent prosecution, litigation, and financing capital equipment acquisitions for their customers.

HSH operates in the healthcare industry and seeks to implement and operate innovative health care models to create a patient-centered, physician-centric experience.

According to the US Bureau of Labor Statistics’ Occupational Outlook Handbook dated as of September 1, 2020, employment in healthcare occupations is projected to grow 15% from 2019 to 2029, much faster than the average for all occupations, adding about 2.4 million new jobs. Healthcare occupations are projected to add more jobs than any of the other occupational groups. This projected growth is mainly due to an aging population, leading to greater demand for healthcare services.

According to a report titled “Ambulatory Surgery Centers Market by Product, By Component, By Specialty Type, and By Geography - Global Drivers, Restraints, Opportunities, Trends, and Forecast up to 2026” released by Research and Markets dated November 29, 2020, the estimated market value of Ambulatory Surgery Centers in 2020 was $1.89 billion.

Ambulatory Surgery Centers are transforming healthcare delivery as well as the market for medical devices and equipment. By focusing on ~~Form 10-K~~routine, lower-risk procedures in a more convenient setting, ASCs can offer surgical procedures at rates 35% to 50% lower than hospitals, according to a September 2019 report published by Bain & Company.

The Urgent Care Association released its 2019 benchmarking report that showed the total number of centers had reached 9,616 as of November 2019, a 9.6% jump from the previous year. The number of Urgent Care Centers has increased steadily each year from 2013, when the total number of Urgent Care Centers was 6,100. Both Urgent Care Centers and ~~incorporated herein by reference.~~Retail Clinics have continued to grow across the US as patients look for convenience and affordability, creating competition with traditional hospital and physician practice services.

Factors which are driving the market growth of Ambulatory Surgical Centers are an increase in the number of surgeries, a rise in the incidence of chronic diseases, and growth in the geriatric population. In addition to the above-mentioned factors, the advancements in technology, and surging demand for minimally invasive surgeries are fueling the growth of the Ambulatory Surgical Center market. The ASCs are more economical as compared to the hospitals and nursing homes as they help patients with instant medical services and quick discharge facilities.

There is a demand to reduce increasing healthcare costs and move from inpatient to outpatient surgical procedures. The rising need of IT solutions such as Telehealth, and Remote Monitoring of the patient for better management creates the market opportunity for Ambulatory Surgical Centers vendors to fulfill both the residential as well as commercial demand.

The rising number of diseases and demand for outpatient surgery has heightened the growth of the Ambulatory Surgical Centers. The ASCs are more economical as compared to the hospitals and nursing homes as they help patients with instant medical services and quick discharge facilities. Further, the vendors of Ambulatory Surgical Centers are spending huge capital in acquiring companies in order to develop innovative and technologically advanced Ambulatory Surgical Centers that can offer surgical treatment for various diseases.

The growing rate of old age population and high occurrence of chronic diseases, gastrointestinal, diabetes resulting in eye related diseases, musculoskeletal and other diseases are the major drivers behind the opening of the technologically advanced Ambulatory Surgery Centers equipped with improved pain operating methods in the United States. The US ASC market is expected to grow at a remarkable pace in future. The demand for highly advanced ambulatory surgical centers is getting stronger all across the United States on the account of positive government initiatives to develop advanced healthcare infrastructure which is further offering opportunities for various ambulatory surgical center companies to expand their presence in the United States.

As a healthcare company, we are subject to various laws and regulations governing our business. For example, all of our comprehensive care locations need to be licensed with the Centers for Medicare and Medicaid Services and state medical boards along with all of the ~~date~~physicians and nurse practitioners that are providing the medical care. All Ambulatory Surgery Centers must also go through a complex licensing procedure with the state in which they are located as well as all of the medical staff at each location.

Our operations and relationships with healthcare providers such as doctors, MSOs, hospitals, other healthcare facilities, and healthcare professionals are subject to extensive and increasing regulation by numerous federal, state, and local government entities. These laws and regulations often are interpreted broadly and enforced aggressively by multiple government agencies, including the U.S. Department of Health and Human Services Office of the Inspector General, the U.S. Department of Justice, Centers for Medicare and Medicaid, and various state authorities. We have included brief descriptions of some, but not all, of the laws and regulations that affect our business below.

Imposition of liabilities associated with a violation of any of these healthcare laws and regulations could have a material adverse effect on our business, financial condition, and results of operations. The Company cannot guarantee that its arrangements or business practices will not be subject to government scrutiny or be found to violate certain healthcare laws. Government investigations and prosecutions, even if we are ultimately found to be without fault, can be costly and disruptive to our business. Moreover, changes in healthcare legislation or government regulation may restrict our existing operations, limit the expansion of our business, or impose additional compliance requirements and costs, any of which could have a material adverse effect on our business, financial condition, and results of operations.

The federal False Claims Act imposes civil liability on individuals or entities that submit false or fraudulent claims for payment to the federal government. The False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the False Claims Act in the name of the government and may share in the proceeds of a successful suit.

The federal government has used the False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs. By way of illustration, these prosecutions may be based upon alleged coding errors, billing for services not rendered, billing services at a higher payment rate than appropriate, and billing for care that is not considered medically necessary. The government and a number of courts also have taken the position that claims presented in violation of certain other statutes, including the federal Anti-Kickback Statute or the Stark Law, can be considered a violation of the False Claims Act based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement.

Penalties for False Claims Act violations include fines ranging from $5,500 to $11,000 for each false claim, plus up to three times the amount of damages sustained by the government. A False Claims Act violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation in governmental healthcare programs, including Medicare and Medicaid. In addition to the provisions of the False Claims Act, which provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government.

A number of states have enacted false claims acts that are similar to the federal False Claims Act. Even more states are expected to do so in the future because Section 6031 of the Deficit Reduction Act of 2005 (“DRA”), amended the federal law to encourage these types of changes, along with a corresponding increase in state initiated false claims enforcement efforts. Under the DRA, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets certain other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under the state’s false claims act. The Office of Inspector General (“OIG”), in consultation with the Attorney General of the United States, is responsible for determining if a state’s false claims act complies with the statutory requirements.

The federal Anti-Kickback Statute is a provision of the Social Security Act that prohibits as a felony offense the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (1) the referral of a patient for items or services for which payment may be made in whole or part under Medicare, Medicaid or other federal healthcare programs, (2) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other federal healthcare programs or (3) the purchase, lease, or order or arranging or recommending the purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The Affordable Care Act (“ACA”) amended section 1128B of the Social Security Act to make it clear that a person need not have actual knowledge of the statute, or specific intent to violate the statute, as a predicate for a violation. The OIG, which has the authority to impose administrative sanctions for violation of the statute, has adopted as its standard for review a judicial interpretation which concludes that the statute prohibits any arrangement where even one purpose of the remuneration is to induce or reward referrals. A violation of the Anti-Kickback Statute is a felony punishable by imprisonment, criminal fines of up to $25,000, civil fines of up to $50,000 per violation and three times the amount of the unlawful remuneration. A violation also can result in exclusion from Medicare, Medicaid, or other federal healthcare programs. In addition, pursuant to the changes of the ACA, a claim that includes items or services resulting from a violation of the Anti-Kickback Statute is a false claim for purposes of the False Claims Act.

Due to the breadth of the Anti-Kickback Statute’s broad prohibitions, statutory exceptions exist that protect certain arrangements from prosecution. In addition, the OIG has published safe harbor regulations that specify arrangements that also are deemed protected from prosecution under the Anti-Kickback Statute, provided all applicable criteria are met. The failure of an activity to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute, but these arrangements may be subject to scrutiny and prosecution by enforcement agencies.

Some states have enacted statutes and regulations similar to the Anti-Kickback Statute, but which may be applicable regardless of the payor source for the patient. These state laws may contain exceptions and safe harbors that are different from and/or more limited than those of the federal law and that may vary from state to state.

The federal Stark Law, also known as the physician self-referral law, generally prohibits a physician from referring Medicare and Medicaid patients to an entity (including hospitals) providing ‘‘designated health services,’’ if the physician or a member of the physician’s immediate family has a ‘‘financial relationship’’ with the entity, unless a specific exception applies. Designated health services include, among other services, inpatient and outpatient hospital services, clinical laboratory services, certain imaging services, and other items or. The prohibition applies regardless of the reasons for the financial relationship and the referral; and therefore, unlike the federal Anti-Kickback Statute, intent to violate the law is not required. Like the Anti-Kickback Statute, the Stark Law contains a number of statutory and regulatory exceptions intended to protect certain types of transactions and business arrangements from penalty. Unlike safe harbors under the Anti-Kickback Statute with which compliance is voluntary, an arrangement must comply with every requirement of a Stark Law exception, or the arrangement is in violation of the Stark Law.

The penalties for violating the Stark Law can include the denial of payment for services ordered in violation of the statute, mandatory refunds of any sums paid for such services and civil penalties of up to $15,000 for each violation, double damages, and possible exclusion from future participation in the governmental healthcare programs. A person who engages in a scheme to circumvent the Stark Law’s prohibitions may be fined up to $100,000 for each applicable arrangement or scheme.

Some states have enacted statutes and regulations similar to the Stark Law, but which may be applicable to the referral of patients regardless of their payor source and which may apply to different types of services. These state laws may contain statutory and regulatory exceptions that are different from those of the federal law and that may vary from state to state.

Because the Stark Law and its implementing regulations continue to evolve, we do not always have the benefit of significant regulatory or judicial interpretation of this ~~Annual Report, the Merger has not been consummated;~~law and ~~neither HSH nor the Company has exercised~~ its ~~termination rights. The Company is currently in discussions with HSH to extend the date provided to consummate the Merger Agreement from September 30, 2020 to a later date, however there~~regulations. There can be no ~~assurances~~assurance that ~~such discussions~~the arrangements entered into by us with physicians and facilities will be ~~successful.~~found to be in compliance with the Stark Law, as it ultimately may be implemented or interpreted.

Among other directives, the Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), required the Department of Health and Human Services, or the HHS, to adopt standards to protect the privacy and security of certain health-related information. The HIPAA privacy regulations contain detailed requirements concerning the use and disclosure of individually identifiable health information by “HIPAA covered entities,” which include entities like the Company, and the providers we may work with.

In addition to the privacy requirements, HIPAA covered entities must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality and availability of certain electronic health information received, maintained, or transmitted. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.

The American Recovery and Reinvestment Act enacted on February 18, 2009, included the Health Information Technology for Economic and Clinical Health Act (HITECH) which modified the HIPAA legislation significantly. Pursuant to HITECH, certain provisions of the HIPAA privacy and security regulations become directly applicable to “HIPAA business associates”.

Violations of the HIPAA privacy and security standards may result in civil and criminal penalties. Historically, these included: (1) civil money penalties of $100 per incident, to a maximum of $25,000, per person, per year, per standard violated and (2) depending upon the nature of the violation, fines of up to $250,000 and imprisonment for up to ten years. The passage of HITECH significantly modified the enforcement structure, creating a tiered system of civil money penalties that range from $100 to $50,000 per violation, with a cap of $1.5 million per year for identical violations. We must also comply with the “breach notification” regulations, which implement certain provisions of HITECH. Under these regulations, in addition to reasonable remediation, covered entities must promptly notify affected individuals in the case of a breach of “unsecured PHI,” which is defined by HHS guidance, as well as the HHS Secretary and the media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to the HHS Secretary on an annual basis. The regulations also require business associates of covered entities to notify the covered entity of breaches at or by the business associate.

Many states also have laws that protect the privacy and security of confidential, personal information. These laws may be similar to or even more stringent than the federal provisions. Not only may some of these state laws impose fines and penalties upon violators, but some may afford private rights of action to individuals who believe their personal information has been misused.

In addition to privacy and security laws focused on health care data, multiple other federal and state laws regulate the use and disclosure of consumer’s financial information (“Personal Information”). Many of these laws also require administrative, technical, and physical safeguards to prevent unauthorized use or disclosure of Personal Information, including mandated processes and timeframes for notification of possible or actual breaches of Personal Information to the affected individual. The Federal Trade Commission primarily oversees compliance with the federal laws relevant to us, while state laws are addressed by the state attorney general or other respective state agencies. As with HIPAA, enforcement of laws protecting financial information is increasing. Examples of relevant federal laws include the Fair Credit Reporting Act, the Electronic Communications Privacy Act, and the Computer Fraud and Abuse Act.

In 1995, Congress amended the federal criminal statutes set forth in Title 18 of the United States Code by defining additional federal crimes that could have an impact on our business, including “Health Care Fraud” and “False Statements Relating to Health Care Matters.” The Health Care Fraud provision prohibits any person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program. As defined in this provision of Title 18, a “healthcare benefit program” can be either a government or private payor plan. Violation of this statute may be charged as a felony offense and may result in fines, imprisonment, or both. The ACA amended section 1347 of Title 18 to provide that a person may be convicted under the Health Care Fraud provision even in the absence of proof that the person had actual knowledge of, or specific intent to violate, the statute.

The False Statements Relating to Health Care Matters provision prohibits, in any matter involving a federal health care program, anyone from knowingly and willfully falsifying, concealing, or covering up, by any trick, scheme or device, a material fact, or making any materially false, fictitious, or fraudulent statement or representation, or making or using any materially false writing or document knowing that it contains a materially false or fraudulent statement. A violation of this statute may be charged as a felony offense and may result in fines, imprisonment, or both.

Under the Civil Monetary Penalties law of the Social Security Act, a person, including any individual or organization, may be subject to civil monetary penalties, treble damages, and exclusion from participation in federal health care programs for certain specified conduct. One provision of the Civil Monetary Penalties law precludes any person (including an organization) from knowingly presenting or causing to be presented to any United States officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services that the person knows or should know (a) were not provided as described in the coding of the claim, (b) is a false or fraudulent claim, (c) is for a service furnished by an unlicensed physician, (d) is for medical or other items or service furnished by a person or an entity that is in a period of exclusion from the program or (e) are medically unnecessary items or services. Violations of the law may result in penalties of up to $10,000 per claim, treble damages, and exclusion from federal healthcare programs. In addition, the OIG may impose civil monetary penalties against any physician who knowingly accepts payment from a hospital (as well as against the hospital making the payment) as an inducement to reduce or limit services provided to Medicare or Medicaid program beneficiaries. Further, except as specifically permitted under the Civil Monetary Penalties law, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider of Medicare or Medicaid payable items or services may be liable for civil money penalties of up to $10,000 for each wrongful act.

In addition to the state laws previously described, we also are subject to other state fraud and abuse statutes and regulations. Many of the states in which we operate or plan to expand to have adopted a form of anti-kickback law, self-referral prohibition, and false claims and insurance fraud prohibition. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Generally, state laws reach to all healthcare services and not just those covered under a governmental healthcare program. A determination of liability under any of these laws could result in fines and penalties and restrictions on our ability to operate in these states. We cannot assure that our arrangements or business practices will not be subject to government scrutiny or be found to violate applicable fraud and abuse laws.

The providers we may work with are subject to numerous federal, state, and local licensing laws and regulations, relating to, among other things, professional credentialing, and professional ethics. Since the Company provides its services to healthcare facilities, it may indirectly be subject to laws applicable to those entities as well as ethical guidelines and operating standards of professional trade associations and private accreditation commissions, such as the American Medical Association and The Joint Commission. There are penalties for non-compliance with these laws and standards, including loss of professional license, civil or criminal fines and penalties, loss of hospital admitting privileges, and exclusion from participation in various governmental and other third-party healthcare programs. Our ability to operate profitably will depend, in part, upon our ability and the ability of the providers to obtain and maintain all necessary licenses and other approvals and operate in compliance with applicable health care laws and regulations, including any new laws and regulations or new interpretations of existing laws and regulations.

The Company ~~believes~~does not currently own any patents or trademarks. The Company expects to rely on trade secrets and proprietary know-how protection for our confidential and proprietary information, however we have not yet taken security measures to protect this information.

We currently have 50 full time employees, 12 consultants, 6 independently contracted sales representatives and 4 part time employees.

On March 11, 2020, the ~~Merger~~World Health Organization declared the COVID-19 outbreak to be a global pandemic which continued to spread throughout the U.S. and the globe. In addition to the devastating effects on human life, the pandemic is continuing to have a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. COVID-19 has already hindered or slowed many of HSH’s businesses, including but not limited to our growth and growth strategies, developments in the marketplace for products, therapies and services, financial results, research and development strategy, regulatory approvals, and competitive strengths. The direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition, continues today, but HSH has thus far weathered the pandemic storm and continues to seek to improve our level of service and patient care. The extent of the ultimate impact of the pandemic on the Company’s operational and financial performance will depend on various developments, including the duration and continued spread of the outbreak, which cannot be ~~consummated, however, there can~~reasonably predicted at this time. Accordingly, while management reasonably expects the COVID-19 outbreak to negatively impact the Company, the related consequences and duration are highly uncertain and cannot be ~~no assurances.~~predicted at this time.

We intend to furnish our shareholders’ annual reports containing financial statements audited by our independent registered public accounting firm and to make available quarterly reports containing unaudited financial statements for each of the first three quarters of each year. We file Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission in order to meet our timely and continuous disclosure requirements. We may also file additional documents with the Commission if they become necessary in the course of our company’s operations.

The public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site is www.sec.gov.

YOU SHOULD CAREFULLY CONSIDER THE RISKS AND UNCERTAINTIES DESCRIBED BELOW AND THE OTHER INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS ANNUAL REPORT ON FORM 10-K BEFORE DECIDING WHETHER TO INVEST IN THE COMPANY’S COMMON STOCK. ADDITIONAL RISKS AND UNCERTAINTIES NOT PRESENTLY KNOWN TO THE COMPANY OR THAT THE COMPANY CURRENTLY DEEMS IMMATERIAL MAY ALSO IMPAIR THE COMPANY’S BUSINESS OPERATIONS. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, THE COMPANY’S BUSINESS, FINANCIAL CONDITION OR OPERATING RESULTS COULD BE MATERIALLY ADVERSELY AFFECTED. IN SUCH CASE, THE TRADING PRICE OR THE COMPANY’S COMMON STOCK COULD DECLINE AND YOU MAY LOSE PART OR ALL OF YOUR INVESTMENT. THIS ANNUAL REPORT ON FORM 10-K ALSO CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. PLEASE SEE “CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS”.

~~We are currently~~The Company was previously in ~~receivership and there can be no assurance that the planned reorganization can be completed or that the Receiver will be discharged as planned.~~receivership.

The Company ~~is currently~~was previously in receivership. On May 16, 2016, pursuant to Case Number A16-733815-B, Nevada’s 8th Judicial District, Business Court, appointed Robert Stevens as receiver (the “Receiver”) for the Company. Creditors of the Company were required to provide claims in writing under oath on or before November 3, 2016, or they would be barred under Nevada Revised Statute §78.675. Since May 16, 2016, through the date of ~~this Annual Report,~~the Merger, the Company ~~has been~~was operating under the direction of the Receiver. On March ~~22,~~5, 2018, the District Court in Clark County, Nevada approved a plan of reorganization ~~that involved authorizing~~for the ~~cancellation~~Company and the discharge of ~~all preferred shares~~the Receiver upon completion of his duties under the court order. Upon the Closing of the Merger, the reorganization of the Company the cancellation of certain insider shares, a reverse stock split up to a maximum of 200-1, and a reorganization that would place the liquidation of the Company’s assets under a liquidating trustee while maintaining the public, purchasers for value with equitydescribed in the ~~surviving entity. Once~~court order was completed and, as a result and pursuant to the ~~reorganization is completed~~court order dated March 5, 2018, the Receiver ~~will be discharged. There can be~~was automatically discharged and the receivership was automatically terminated such that no ~~assurance that the planned reorganization can be completed or that~~further action was needed by the Receiver ~~will be discharged as planned.~~or the Company in connection with the receivership, and such that Company was no longer in receivership.

~~We have a history of operating losses and our~~Our auditors have indicated that there is substantial doubt about our ability to continue as a going concern.

~~The Company is currently in receivership. The Company’s~~Our financial statements have been ~~presented on the basis~~prepared assuming that ~~it is~~we will continue as a going concern, which contemplates ~~the~~ realization of assets and the satisfaction of liabilities in the normal course of ~~business. At June 30, 2020,~~business for the twelve-month period following the date of the financial statements for the Company included elsewhere in this report. We have incurred significant operating losses since inception. Because we do not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about our ability to continue as a going concern. Therefore, we will need to raise additional funds and is currently exploring alternative sources of financing. On September 30, 2021, we had ~~a retained~~an accumulated deficit of ~~$13,075,376 and~~$29,171,161. Excluding investments of $89,823,346 which are not intended to be used for working capital, we had negative working capital of ~~$4,384,704.~~$11,168,765. The financial statements do not include any adjustments that might be necessary if ~~the Company is~~we are unable to continue as a going concern. ~~The Company’s~~Our continuation as a going concern is ~~solely~~ dependent upon the ~~Receiver’s~~ ability to raise financing from third ~~parties.~~parties and generating revenues from operations. There is no assurance that ~~the Company~~we will be successful in doing so. For further discussion about our ability to continue as a going concern and our plan for future liquidity, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

~~Because~~We are an early-stage company with a limited operating history. Such limited operating history may not provide an adequate basis to judge our future prospects and results of operations.

We have a limited operating history. HSH was formed on November 27, 2017. We have limited experience and operating history in which to assess our future prospects as a company. In addition, the market for our products and services is highly competitive. If we ~~are a “shell company” the holders of~~fail to successfully develop and offer our ~~restricted securities will~~products and services in an increasingly competitive market, we may not be able to ~~sell their securities in reliance on Rule 144~~capture the growth opportunities associated with them or recover our development and ~~we cannot file registration statements under Section 5~~marketing costs, and our future results of ~~the Securities Act using~~operations and growth strategies could be adversely affected. Our limited history may not provide a ~~Form S-8, until we cease being a “shell company”.~~meaningful basis for investors to evaluate our business, financial performance, and prospects.

We are a “shell company” as that term is defined by the applicable federal securities laws. Applicable provisions of Rule 144 specify that during that time that we are a “shell company” and for a period of one year thereafter, holders of our restricted securities cannot sell those securities in reliance on Rule 144. This restriction may have potential adverse effects on future efforts to form additional capital through unregistered offerings. Another implication of us being a shell company is that we cannot file registration statements under Section 5 of the Securities Act using a Form S-8, a short form of registration to register securities issued to employees and consultants under an employee benefit plan. As result, one year after we cease being a shell company, assuming we are “current” in our reporting requirements with the Securities and Exchange Commission and have filed current “Form 10 information” with the SEC reflecting our status as an entity that is no longer a shell company for a period of not less than 12 months, holders of our restricted securities may then sell those securities in reliance on Rule 144 (provided, however, those holders satisfy all of the applicable requirements of that rule). We are currently a shell company, and while we believe that as a result of the planned Merger, the Company will cease to be a shell company, the SEC and others whose approval is required in order for shares to be sold under Rule 144 or for a Form S-8 filing, might take a different view. Additionally there can be no assurance that the Merger can close as planned, or at all.

Our shareholders may lose their entire investment if we fail to execute our business plan. Our prospects must be considered in light of the following risks and uncertainties, including but not limited to, competition, the erosion of ongoing revenue streams, the ability to retain experienced personnel and general economic conditions. We cannot guarantee that we will be successful in executing our business plan. If we fail to successfully execute our business plan, we may be forced to cease operations, in which case our shareholders may lose their entire investment.

We have a history of losses and may have to further reduce our costs by curtailing future operations to continue as a business.

Historically we have had operating losses and our cash flow has been inadequate to support our ongoing operations. Our ability to fund our capital requirements out of our available cash and cash generated from our operations depends on a number of factors, including our ability to gain interest in our products and services and continue growing our existing operations. If we cannot continue to generate positive cash flow from operations, we will have to reduce our costs and try to raise working capital from other sources. These measures could materially and adversely affect our ability to execute our operations and expand our business.

We expect to have ongoing needs for working capital in order to fund operations and to continue to expand our operations. To that end, we will be required to raise additional funds through equity or debt financing. However, there can be no assurance that we will be successful in securing additional capital on favorable terms, if at all. If we are successful, whether the terms are favorable or unfavorable, there is a potential that we will fail to comply with the terms of such financing, which could result in severe liability for our Company. If we are unsuccessful, we may need to (a) initiate cost reductions; (b) forego business development opportunities; (c) seek extensions of time to fund liabilities, or (d) seek protection from creditors. In addition, any future sale of our equity securities would dilute the ownership and control of your shares and could be at prices substantially below prices at which our shares currently trade. Our inability to raise capital could require us to significantly curtail or terminate our operations altogether. We may seek to increase our cash reserves through the sale of additional equity or debt securities. The sale of convertible debt securities or additional equity securities could result in additional and potentially substantial dilution to our shareholders. The incurrence of indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations and liquidity. In addition, our ability to obtain additional capital on acceptable terms is subject to a variety of uncertainties.

In addition, if we are unable to generate adequate cash from operations, and if we are unable to find sources of funding, it may be necessary for us to sell all or a portion of our assets, enter into a business combination, or reduce or eliminate operations. These possibilities, to the extent available, may be on terms that result in significant dilution to our shareholders or that result in our shareholders losing all of their investment in our Company.

We expect that we will pursue acquisitions of other businesses, assets, or technologies to grow our business. We may fail to identify attractive acquisition candidates, or we may be unable to reach acceptable terms for future acquisitions. We might not be able to raise enough cash to compete for attractive acquisition targets. If we are unable to complete acquisitions in the future, our ability to grow our business at our anticipated rate will be impaired.

We may pay for acquisitions by issuing additional shares of our common stock, which would dilute our stockholders, or by issuing debt, which could include terms that restrict our ability to operate our business or pursue other opportunities and subject us to meaningful debt service obligations. We may also use significant amounts of cash to complete acquisitions. To the extent that we complete acquisitions in the future, we likely will incur future depreciation and amortization expenses associated with the acquired assets. We may also record significant amounts of intangible assets, including goodwill, which could become impaired in the future. Acquisitions involve numerous other risks, including:

Our management team’s attention may be diverted by recent acquisitions and searches for new acquisition targets, and our business and operations may suffer adverse consequences as a result.

Mergers and acquisitions are time intensive, requiring significant commitment of our management team’s focus and resources. If our management team spends too much time focused on recent acquisitions or on potential acquisition targets, our management team may not have sufficient time to focus on our existing business and operations. This diversion of attention could have material and adverse consequences on our operations and our ability to be profitable.

The ~~recent~~continued outbreak of the coronavirus may cause an overall decline in the economy as a whole and may materially harm our Company.

IfOn March 11, 2020, the ~~recent~~World Health Organization declared the COVID-19 outbreak to be a global pandemic which continued to spread throughout the U.S. and the globe. In addition to the devastating effects on human life, the pandemic is continuing to have a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. COVID-19 ~~coronavirus~~has already hindered or slowed many of HSH’s businesses, including but not limited to our growth and growth strategies, developments in the marketplace for products, therapies and services, financial results, research and development strategy, regulatory approvals, and competitive strengths. The direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition, continues today, but HSH has thus far weathered the pandemic storm and continues to ~~grow, the effects~~seek to improve our level of ~~such a widespread infectious disease~~service and ~~epidemic may cause an overall decline in the economy as a whole.~~patient care. The ~~actual effects~~extent of the ~~spread~~ultimate impact of ~~coronavirus are difficult to assess at this time as~~ the ~~actual effects~~pandemic on the Company’s operational and financial performance will depend on ~~many factors beyond~~various developments, including the ~~control~~duration and ~~knowledge of the Company. However, the~~continued spread of the ~~coronavirus, if it continues may cause an overall decline in the economy as a whole and therefore may materially harm our Company.~~outbreak, which cannot be reasonably predicted at this time. Accordingly, while management reasonably expects the COVID-19 outbreak to negatively impact the Company, the related consequences and duration are highly uncertain and cannot be predicted at this time.

Our growth strategy will place significant demands on our management and financial, administrative, and other resources. Operating results will depend substantially on the ability of our officers and key employees to manage changing business conditions and to implement and improve our financial, administrative, and other resources. If the Company is unable to respond to and manage changing business conditions, or the scale of its operations, then the quality of its services, its ability to retain key personnel, and its business could be harmed.

By incurring indebtedness, the Company subjects itself to increased debt service obligations which could result in operating and financing covenants that would restrict our operations and liquidity. This would impair our ability to hire the necessary senior and support personnel required for our business, as well as carry out its acquisition strategy and other business objectives.

Economic conditions or changing consumer preferences could adversely impact our business.

A downturn in economic conditions in one or more of the Company’s ~~future~~ markets could have a material adverse effect on our results of operations, financial condition, business, and prospects. In addition, an economic downturn, coupled with sustained unemployment, may also impact the number of enrollees in managed care programs as well as the profitability of managed care companies, which could result in reduced reimbursement rates. The existing federal deficit, as well as deficit spending by the government as the result of adverse developments in the economy or other reasons, can lead to continuing pressure to reduce government expenditures for other ~~purposes.~~purposes, including government-funded programs in which we participate, such as Medicare and Medicaid. Such actions in turn may adversely affect our results of operations. Although we attempt to stay informed of government and customer trends, any sustained failure to identify and respond to trends could have a material adverse effect on our results of operations, financial condition, business, and prospects.

The Company’s success depends upon the ability to adapt to a changing market and continued development of additional products and services.

Although we expect to provide a broad and competitive range of products and services, there can be no assurance of acceptance by the marketplace. The procurement of new contracts by the Company may be dependent upon the continuing results achieved, upon pricing and operational considerations, as well as the potential need for continuing improvement to existing products and services. Moreover, the markets for such products and services may not develop as expected nor can there be any assurance that we will be successful in our marketing of any such services.

The healthcare industry is competitive, and we may not be able to compete effectively.

There are other companies and individuals currently providing similar products and services as us in the healthcare industry. We compete directly with national, regional, and local companies. Other companies could enter the market in the future and divert some or all of our business. Our competitors may have greater financial and other resources available to them. Existing or future competitors also may seek to compete with us for acquisitions, which could have the effect of increasing the price and reducing the number of suitable acquisitions, which would have an adverse impact on our growth strategy. We may be unable to successfully compete with these competitors and may expend significant resources without success.

The requirements of remaining a public company may strain our resources and distract our management, which could make it difficult to manage our business.

We are required to comply with various regulatory and reporting requirements, including those required by the SEC. Complying with these reporting and other regulatory requirements are time-consuming and expensive and could have a negative effect on our business, results of operations and financial condition.

The commercial success of our products and services is dependent upon unpredictable and volatile factors beyond our control, such as the success of our competitors’ products and services. Our failure to attract market acceptance and a sustainable competitive advantage over our competitors would materially harm our business.

We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”) and if we fail to continue to comply, our business could be harmed, and the price of our securities could decline.

Rules adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley Act require an annual assessment of internal control over financial reporting, and for certain issuers an attestation of this assessment by the issuer’s independent registered public accounting firm. The standards that must be met for management to assess the internal control over financial reporting as effective are evolving and complex, and require significant documentation, testing, and possible remediation to meet the detailed standards. We expect to incur significant expenses and to devote resources to Section 404 compliance on an ongoing basis. It is difficult for us to predict how long it will take or costly it will be to complete the assessment of the effectiveness of our internal control over financial reporting for each year and to remediate any deficiencies in our internal control over financial reporting. As a result, we may not be able to complete the assessment and remediation process on a timely basis. In the event that ~~we determine~~our Chief Executive Officer or Chief Financial Officer determines that our internal control over financial reporting is not effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our securities will be affected; however, we believe that there is a risk that investor confidence and the market value of our securities may be negatively affected.

We are currently delinquent in our SEC Reporting Obligations for the periodic reports due to be filed from June 2014 to March 2019, as well as for the periodic reports due to be filed for the quarters ended December 31, 2021 and March 31, 2022. The Company plans to make up the foregoing reports, however, there can be no assurance that it will be able to do so as planned. If we are unable to make up such delinquent periodic reports, it may cause difficulties in FINRA processing any corporate actions submitted by the Company as well as difficulty moving up from the Expert Market to the OTC Pink Tier. Additionally, our ability to obtain additional financing could be impaired or a lack of investor confidence in the reliability and accuracy of our public reporting could cause our stock price to decline.

The healthcare industry is complex and intensely regulated at the federal, state, and local levels and government authorities may determine that we have failed to comply with applicable laws or regulations.

As a company involved in the provision of healthcare services, we are subject to a myriad of federal, state, and local laws and regulations. There are significant costs involved in complying with these laws and regulations. Moreover, if we are found to have violated any applicable laws or regulations, we could be subject to civil and/or criminal damages, fines, sanctions, or penalties, including exclusion from participation in governmental healthcare programs, such as Medicare and Medicaid. We may also be required to change our method of operations. These consequences could be the result of current conduct or even conduct that occurred a number of years ago. We also could incur significant costs merely if we become the subject of an additional investigation or legal proceeding alleging a violation of these laws and regulations. We cannot predict whether a federal, state, or local government will determine that we are not operating in accordance with law, or whether the laws will change in the future and impact our business. Any of these actions could have a material adverse effect on our business, financial condition, and results of operations.

The following is a non-exhaustive list of some of the more significant healthcare laws and regulations that affect us:

Our revenue may be negatively impacted by the failure of our providers to appropriately document services they provide.

We rely upon our providers to appropriately and accurately complete necessary medical record documentation and assign appropriate reimbursement codes for their services. If our providers have provided incorrect or incomplete documentation or selected inaccurate reimbursement codes, this could result in nonpayment for services rendered or lead to allegations of billing fraud. This could subsequently lead to civil and criminal penalties, including exclusion from government healthcare programs, such as Medicare and Medicaid. In addition, third-party payors may disallow, in whole or in part, requests for reimbursement based on determinations that certain amounts are not covered, services provided were not medically necessary, or supporting documentation was not adequate. Retroactive adjustments may change amounts realized from third-party payors and result in recoupments or refund demands, affecting revenue already received.

Changes associated with reimbursement by third-party payors for the Company’s services may adversely affect operating results and financial condition.

The medical services industry is undergoing significant changes with third-party payors that are taking measures to reduce reimbursement rates or in some cases, denying reimbursement altogether. There is no assurance that third-party payors will continue to pay for the services provided by our providers which will have a material adverse effect on our results of operations, financial condition, business, and prospects.

Compliance with federal and state privacy and information security laws is expensive, and we may be subject to government or private actions due to privacy and security breaches.

We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security, and confidentiality of patient health information (“PHI”), including HIPAA and HITECH. Despite our efforts to prevent security and privacy breaches, they may still occur. If any non-compliance with existing or new laws and regulations related to PHI results in privacy or security breaches, we could be subject to monetary fines, civil suits, civil penalties, or even criminal sanctions. As a result of the expanded scope of HIPAA through HITECH, we may incur significant costs in order to minimize the amount of “unsecured PHI” we handle and retain or to implement improved administrative, technical, or physical safeguards to protect PHI. We may incur significant costs in order to demonstrate and document whether there is a low probability that the PHI has been compromised in order to overcome the presumption that an impermissible use or disclosure of PHI results in a reportable breach. We may incur significant costs to notify the relevant individuals, government entities, and, in some cases, the media, in the event of a breach and to provide appropriate remediation and monitoring to mitigate the possible damage done by any such breach.

If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting healthcare reform or the healthcare industry, our business may be harmed.

Due to the importance of the healthcare industry in the lives of all Americans, federal, state, and local legislative bodies frequently pass legislation and promulgate regulations relating to healthcare reform or that affect healthcare business. It is reasonable to believe that there may be increased federal oversight and regulation of the healthcare industry in the future. We cannot assure you as to the ultimate content, timing, or effect of any healthcare reform legislation, nor is it possible at this time to estimate the impact of potential legislation on our business. It is possible that future legislation enacted by Congress or state legislatures could adversely affect our business or could change the operating environment of our providers to which we provide our products and services. It is possible that the changes to the Medicare or other governmental healthcare program reimbursements may serve as precedent to possible changes in other payors’ reimbursement policies in a manner adverse to us. Similarly, changes in private payor reimbursements could lead to adverse changes in Medicare and other governmental healthcare programs which could have a material adverse effect on our business, financial condition, and results of operations.

Our ~~common stock currently trades~~Common Stock Currently Trades on the ~~Pink~~Expert Market Tier of OTC Marketsand is Labeled ~~as “No Information” and~~ as “Delinquent SEC Reporting.”

Our common stock currently trades on the ~~Pink~~Expert Market Tier of OTC Market Group LLC’s Marketplace under the symbol ~~“VRTY”~~“HSMD” and is labeled ~~as “No Information” and~~ as “Delinquent SEC Reporting” at this time. ~~The Company plans to update its symbol pending FINRA approval of the Company’s Name Change, which the Company has not yet submitted to FINRA.~~ The OTC Market is a network of security dealers who buy and sell stock. The dealers are connected by a computer network that provides information on current “bids” and “asks,” as well as volume information. ~~The trading of securities~~Stock on the ~~OTC Pink~~Expert Market is ~~often sporadic~~not eligible for proprietary broker-dealer quotations. All quotes in stock on the Expert Market reflect unsolicited customer orders. Unsolicited-Only stocks, such as ours, have a higher risk of wider spreads, increased volatility, and ~~investors~~price dislocations. Investors may have difficulty ~~buying and~~ selling our ~~shares or obtaining~~stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market ~~quotations~~making in our stock. The Expert Market serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for ~~them, which may have a negative effect~~quoting on the ~~market price of our common stock.~~Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting.

Because we are currently delinquent in our SEC filings, the holders of our restricted securities will not be able to sell their securities in reliance on Rule 144.

Because we are currently delinquent in our SEC filings, the holders of our restricted securities will not be able to sell their securities in reliance on Rule 144. Accordingly, at this time, holders of our restricted securities cannot sell those securities in reliance on Rule 144. This restriction may have potential adverse effects on future efforts to form additional capital through unregistered offerings.

Our ~~common stock~~Common Stock is subject to risks arising from restrictions on reliance on Rule 144 by ~~shell companies or~~ former shell companies.

Under a regulation of the SEC known as “Rule 144,” a person who beneficially owns restricted securities of an issuer and who is not an affiliate of that issuer may sell them without registration under the Securities Act provided that certain conditions have been met. One of these conditions is that such person has held the restricted securities for a prescribed period, which will be 6 months for the common stock. However, Rule 144 is unavailable for the resale of securities issued by an issuer that is a shell company (other than a business combination related shell company) or, unless certain conditions are met, that has been at any time previously a shell company.

The SEC defines a shell company as a company that has (a) no or nominal operations and (b) either (i) no or nominal assets, (ii) assets consisting solely of cash and cash equivalents; or (iii) assets consisting of any amount of cash and cash equivalents and nominal other assets.

~~The~~As a result of the Merger as described in Items 1.01 and 2.01, the Company ~~is currently~~ceased being a shell company as such term is defined in Rule 12b-2 under the Exchange Act.

While we believe that as a result of the Merger, the Company ceased to be a shell company, the SEC, and others whose approval is required in order for shares to be sold under Rule 144 might take a different view.

Rule 144 is available for the resale of securities of former shell companies if and for as long as the following conditions are met:

(i) the issuer of the securities that was formerly a shell company has ceased to be a shell company,

(ii) the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act,

(iii) the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K; and

(iv) at least one year has elapsed from the time that the issuer filed current comprehensive disclosure with the SEC reflecting its status as an entity that is not a shell company known as “Form 10 Information.”

Although the Company filed Form 10 Information with the SEC on its Current Report on Form 8-K on April 21, 2021, shareholders who receive the Company’s restricted securities will not be able to sell them pursuant to Rule 144 without registration until the Company has met the other conditions to this exception and then for only as long as the Company continues to meet the condition described in subparagraph (iii), above, and is not a shell ~~company, and while we believe~~company. No assurance can be given that ~~as a result of the planned Merger,~~ the Company will ~~cease~~meet these conditions or that, if it has met them, it will continue to do so, or that it will not again be a shell company, the SEC and others whose approval is required in order for shares to be sold under Rule 144 might take a different view. Additionally there can be no assurance that the Merger can close as planned, or at all.company.

The sale of the additional shares of ~~common stock~~Common Stock could cause dilution as well as the value of our ~~common stock~~Common Stock to decline.

The sale of a substantial number of shares of our common stock, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish. Further, if we do sell or issue more common stock, any investors’ investment in the Company will be diluted. Dilution is the difference between what you pay for your stock and the net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in the Company’s common stock could seriously decline in value.

Our ~~common stock~~Common Stock constitutes restricted securities and is subject to limited transferability.

All of our common stock shares, should be considered a long-term, illiquid investment. Common. In addition, our common stock, is not registered under any state securities laws that would permit their transfer. Because of these restrictions and the absence of an active trading market for our securities, a stockholder will likely be unable to liquidate an investment even though other personal financial circumstances would dictate such liquidation.

Our ~~common stock~~Common Stock price may decrease due to factors beyond our control.

The stock market from time to time has experienced extreme price and volume fluctuations, which have particularly affected the market prices for ~~early stage~~early-stage companies, and which often have been unrelated to the operating performance of the companies. These broad market fluctuations may adversely affect the market price of our stock, if a trading market for our stock ever develops. If our shareholders sell substantial amounts of their stock in the public market, the price of our stock could fall. These sales also might make it more difficult for us to sell equity, or equity-related securities, in the future at a price we deem appropriate.

The market price of our stock may also fluctuate significantly in response, ~~to,~~ but not limited, to the following factors, most of which are beyond our control:

Any such fluctuations may adversely affect the market price or value of our common stock, regardless of our actual operating performance. As a result, stockholders may be unable to sell their shares, or may be forced to sell them at a loss.

Our ~~common stock~~Common Stock is subject to the application of the “penny stock” rules which could adversely affect the market price of our common stock and increase transaction costs to sell those shares.

The SEC has adopted rule 3a51-1 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires:

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

The market price for our ~~common stock~~Common Stocks is particularly volatile which could lead to wide fluctuations in our share price. You may be unable to sell your ~~common stock~~Common Stock shares at or above your purchase price, or at all, which may result in substantial losses to you.

The market for our common stock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer. Many of these factors are beyond our control and may decrease the market price of our common stock, regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for our common stock shares will be at any time, or as to what effect the sale of shares or the availability of common stock shares for sale at any time will have on the prevailing market price.

Because we will likely issue additional shares of our ~~common stock,~~Common Stock, investment in the Company could be subject to substantial dilution.

Investors’ interests in the Company will be diluted and investors may suffer dilution in their net book value per share when we issue additional shares. We are authorized to issue 1,400,000,000 shares of common stock. We anticipate that all or at least some, or potentially all, of our future funding, if any, will be in the form of equity financing from the sale of our common stock. If we do sell or issue more common stock, any investors’ investment in the Company will be diluted. Dilution is the difference between what you pay for your stock and the net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in the Company’s common stock could seriously decline in value.

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.

In addition to the “penny stock” rules described above, FINRA has adopted FINRA Rule 2111 that requires a broker-dealer to have reasonable grounds for believing that an investment is suitable for a customer before recommending the investment. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

We have never declared or paid any cash dividends on our stock and do not intend to pay any cash dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the development of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our Board of Directors.

If we are unable to comply with the financial reporting requirements mandated by the SEC’s regulations, investors may lose confidence in our financial reporting and the price of our common stock, if a market ever does develop for it, could decline.

If we fail to maintain effective internal controls over financial reporting, our ability to produce timely, accurate and reliable periodic financial statements could be impaired. If we do not maintain adequate internal control over financial reporting, investors could lose confidence in the accuracy of our periodic reports filed under the Exchange Act. Additionally, our ability to obtain additional financing could be impaired or a lack of investor confidence in the reliability and accuracy of our public reporting could cause our stock price to decline.

~~The~~Prior to the Merger, the Company’s headquarters ~~are~~were located at 387 Corona St., Suite 555, Denver, CO ~~80218, which are provided~~80218. Since the Merger, the Company no longer uses the foregoing property.

Effective as of the Closing of the Merger, the Company’s principal office is located at 3 School St, Suite 303, Glen Cove, NY 11542, where it leases approximately 2,250 square feet of office space at a monthly rent of $2,500 per month. Pursuant to the ~~Company~~terms of the lease, the monthly rent will go up to $2,575 per month starting on September 15, 2021 and will remain at ~~no cost.~~this amount until September 14, 2022. The lease term ends on September 14, 2022. We believe that these facilities are adequate ~~at this time~~to support the Company’s existing operations and that we will be able to obtain appropriate additional facilities or alternative facilities on commercially reasonable terms if and when necessary.

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Legal expenses associated with any contingency are expensed as incurred. The Company’s officers and directors are not aware of any threatened or pending litigation to which the Company is a party, other than the receivership as discussed below, or which any of its property is the subject and which would have any material, adverse effect on the Company.

The Company ~~is currently~~was previously in receivership. On May 16, 2016, pursuant to Case Number A16-733815-B, Nevada’s 8th Judicial District, Business Court, appointed Robert Stevens as receiver (the “Receiver”) for the Company. Creditors of the Company were required to provide claims in writing under oath on or before November 3, 2016, or they would be barred under Nevada Revised Statute §78.675. Since May 16, 2016, through the date of ~~this Annual Report,~~the Merger, the Company ~~has been~~was operating under the direction of the Receiver. On March ~~22,~~5, 2018, the District Court in Clark County, Nevada approved a plan of reorganization ~~that involved authorizing~~for the ~~cancellation~~Company and the discharge of ~~all preferred shares~~the Receiver upon completion of his duties under the court order. Upon the Closing of the Merger, the reorganization of the Company the cancellation of certain insider shares, a reverse stock split up to a maximum of 200-1, and a reorganization that would place the liquidation of the Company’s assets under a liquidating trustee while maintaining the public, purchasers for value with equitydescribed in the ~~surviving entity. Once~~court order was completed and, as a result and pursuant to the ~~reorganization is completed it is expected~~court order dated March 5, 2018, the Receiver ~~will be discharged.~~was automatically discharged and the receivership was automatically terminated such that no further action was needed by the Receiver or the Company in connection with the receivership, and such that Company was no longer in receivership.

Our common stock ~~Currently Trades~~currently trades on the ~~Pink~~Expert Market Tier of OTC Market Group LLC’s Marketplace under the symbol ~~“VRTY”~~“HSMD” and is labeled ~~as “No Information” and~~ as “Delinquent SEC Reporting” at this time. ~~The Company plans to update its symbol pending FINRA approval of the Company’s name change to its current name, which the Company has not yet submitted to FINRA.~~ The OTC Market is a network of security dealers who buy and sell stock. The dealers are connected by a computer network that provides information on current “bids” and “asks,” as well as volume information. ~~The trading of securities~~Stock on the ~~OTC Pink~~Expert Market is ~~often sporadic~~not eligible for proprietary broker-dealer quotations. All quotes in stock on the Expert Market reflect unsolicited customer orders. Unsolicited-Only stocks, such as ours, have a higher risk of wider spreads, increased volatility, and ~~investors~~price dislocations. Investors may have difficulty ~~buying and~~ selling our ~~shares or obtaining~~stock. An initial review by a broker-dealer under SEC Rule15c2-11 is required for brokers to publish competing quotes and provide continuous market ~~quotations~~making in our stock. The Expert Market serves broker-dealer pricing and investor best execution needs. Quotations in Expert Market securities are restricted from public viewing. OTC Markets Group may designate securities for ~~them, which may have a negative effect~~quoting on the ~~market price of our common stock.~~Expert Market when it is not able to confirm that the company is making current information publicly available under SEC Rule 15c2-11, or when the security is otherwise restricted from public quoting. The ~~closing price of our~~ common stock previously traded on the Pink Tier of OTC ~~Pink~~Market Group LLC’s Marketplace. The dealers are connected by a computer network that provides information on ~~October 2, 2020 was $0.0427.~~current “bids” and “asks,” as well as volume information.

The following table sets forth, for the periods indicated the high and low bid quotations for our common stock. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown, or commission and may not represent actual transactions.

*These prices were adjusted for the Company’s 1 for 115 reverse stock split, which was effective on October 29, 2021. The prices in the remainder of this table were not adjusted for the reverse stock split.

**On November 5, 2020, the Company’s court appointed receiver, acting under judicial order on behalf of the Board of Directors of the Company, in accordance with the Company’s Bylaws, acted by written consent to change the Company’s Fiscal Year end from June 30 to September 30. The high and low bid quotations for our common stock during the period from July 1, 2020 to September 30, 2020, were $0.1950 and $0.0138, respectively.

On September 13, 2021, the Board of Directors (the “Board”) of the “Company approved (i) a 1 for 115 Reverse Stock Split of the Company’s common stock with any fractional shares of common stock resulting therefrom being rounded up to the nearest whole share of common stock (the “Reverse Stock Split”) and (ii) a voluntary change in the Company’s stock symbol from “VRTY” to a symbol selected by the Company’s officers (the “Symbol Change” and together with the Reverse Stock Split, referred to herein together as the “Corporate Actions”). On the same date, 52.42 % of the Company’s shareholders also approved the Corporate Actions. On September 15, 2021, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate”) with the Delaware Secretary of State for the Reverse Stock Split, with an effective date of the later of (i) September 29, 2021 or (ii) on a date that that the Reverse Stock Split, is announced by Financial Industry Regulatory Authority (“FINRA”).

The Company submitted an Issuer Company Related Action Notification regarding the Corporate Actions, as well as its prior name change to its current name to FINRA on September 15, 2021 (the name change together with the Reverse Stock Split and Symbol Change are referred to herein together as the “Corporate Actions”). The Company was then notified by FINRA that the market effective date for the Corporate Actions was October 29, 2021. The new trading symbol for the Company’s common stock as of October 29, 2021 was “VRTYD” and effective as of November 26, 2021 the symbol changed to “HSMD.” Further, the Company’s common stock now has the following CUSIP number: 42226Y 105.

The Company has not declared any dividends since inception and does not anticipate paying any dividends in the foreseeable future on its common stock. The payment of dividends is within the discretion of the Board of Directors and will depend on the Company’s earnings, capital requirements, financial condition, and other relevant factors. There are no restrictions that currently limit the Company’s ability to pay dividends on its common stock other than those generally imposed by applicable state law.

As of ~~October 6, 2020,~~May 31, 2022, we had ~~127,333,060~~92,214,638 shares of our common stock par value, $.0001 issued and outstanding. There were approximately ~~1,486~~1,671 record owners of our common stock.

The Company’s transfer agent Pacific Stock Transfer, located at 4045 South Spencer Street, Suite 403, Las Vegas, NV, 89119.

As disclosed throughout this Report the Company effected a 1 for 115 reverse stock split on October 29, 2021. The following share listed below in this section “Recent Sales of Unregistered Securities”, reflected pre-split share totals, other than for any issuances made after October 29, 2021, which is the effective date of the split.

On August 27, 2020, the Company issued the Receiver Shares, which consisted of 38,199,918 shares each of its common stock to three parties, totaling 114,599,754 shares of common stock in the aggregate, in accordance with the Amendment and the Merger Agreement as consideration for the services provided to the Company by its receiver.

On April 15, 2021 the Company consummated the Merger, whereby 1,145,997,555 shares of the Company’s common stock were issued to the holders of HSH common stock at the Exchange Ratio.

Additionally, subsequent to September 30, 2021, the Company issued 142,198 shares for consulting services.

The above issuances of shares of common stock were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder.

Our authorized capital stock consists of 1,400,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, $0.0001 par value per share, of which ~~127,333,060~~92,214,638 shares of common stock are currently outstanding; and 0-0- shares of preferred stock are currently ~~outstanding.~~outstanding, respectively, as of May 31, 2022.

Each holder of our common stock is entitled to one vote for each share owned of record on all matters voted upon by shareholders, and a majority vote is required for actions to be taken by shareholders. The common stock has no preemptive rights, no cumulative voting rights and no redemption, sinking fund or conversion provisions.

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value per share and the Company’s Board of Directors is authorized to establish, from the authorized shares of preferred stock, one or more classes or series of shares, to designate each such class and series, and fix the rights and preferences of each such class of preferred stock, which shall have voting powers, preferences, participating, optional or other special rights, qualifications and limitations or restrictions as adopted by the Board of Directors prior to the issuance of any such preferred shares.

Provisions of our Bylaws could make it more difficult to acquire us utilizing a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.

Calling of Special Meetings of Stockholders. Our Bylaws provide that special meetings of the stockholders may be called only by the Board, unless otherwise required by law.

The following discussion and analysis of the results of operations and financial condition of the Company for the years ended ~~June~~September 30, ~~2020~~2021 and ~~2019,~~2020, should be read in conjunction with the other sections of this Annual Report, including “Description of Business” and the Financial Statements and notes thereto of the Company included in this Annual Report. The various sections of this discussion contain forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this Annual Report as well as other matters over which we have no control. See “Cautionary Note Regarding Forward-Looking Statements.” Our actual results may differ materially. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report.

Healthcare Solutions Management Group, Inc., a Delaware corporation, and successor in interest to Verity Delaware Inc., a Delaware corporation which was previously a Nevada corporation named Verity Corp. was incorporated on April 11, 2006 in the state of Nevada under the name Infrared Systems, International.

On April 1, 2013, the Company changed its name from AquaLiv Technologies Inc. to Verity Corp. and our stock symbol changed to VRTY.

At the Closing of the Merger, Robert Stevens (the “Receiver”) appointed new officers and directors of the Company. As consideration for the services of the Receiver and his team, for acting as the court-appointed receiver for the Company and its predecessor and affiliated entities, and pursuant the Merger Agreement, as amended, in August of 2020, the Receiver and certain entities, as directed by the Receiver, were issued an aggregate total of 114,599,754 shares of the Company’s common stock. At Closing, the aggregate Merger consideration paid to the holders of the HSH common was 1,145,997,555 shares of the Company’s common stock constituting 90% of the issued and outstanding shares of Company common stock immediately following the Closing.

~~Since Healthcare Solutions Management Group, Inc. became the successor in interest to Verity Delaware Inc. a Delaware corporation which was previously a Nevada corporation named Verity Corp.,~~On November 5, 2020, the Company’s ~~current name is Healthcare Solutions Management Group, Inc. The~~court appointed receiver, acting under judicial order on behalf of the Board of Directors of the Company, ~~plans to submit an Issuer Company-Related Action Notification Form (the “Name Change”) to the Financial Industry Regulatory Authority (“FINRA”) to request that~~in accordance with the Company’s ~~name be updated to its current name and~~Bylaws, acted by written consent to change the Company’s ~~trading symbol accordingly. The Company has not yet submitted the Name Change~~Fiscal Year End from June 30 to ~~FINRA and there can be no assurance that FINRA will process the Name Change as planned, or at all.~~

~~In February 2016, all of the Company’s officers and directors resigned, and the Company stopped substantially all operating activities. Since such time, and currently, the Company is~~September 30. As a ~~“shell company,” as such term is defined in Rule 12b-2 under the Exchange Act. Since May 16, 2016, through the date~~result of this ~~Annual Report, the Company has been operating under the direction of the Receiver.~~

On June 14, 2019, the Company (the successor in interest to Verity Delaware Inc., a Delaware corporation which was previously a Nevada corporation named Verity Corp.) entered into a Merger Agreement (the “Merger Agreement”) by and between the Company, Verity Merger Corp., a wholly-owned subsidiary of the Company (the “Merger Sub”), and Healthcare Solutions Holdings, Inc. (“HSH”). Pursuant to the terms of the Merger Agreement, the parties agreed that Merger Sub would merge with and into HSH, with HSH being the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Merger”).

The closing of the Merger is planned to take place on the third business day following the satisfaction or waiver (by the party for whose benefit the condition exists) of the closing conditions in the Merger Agreement or on such other date and at such other time and place as the parties agree in writing.

~~At the closing of the Merger, it is planned that the Receiver will elect Justin Smith, Jonathan Loutzenhiser and Dr. Charles Balaban as members of the Company’s board of directors, and then resign.~~

As consideration for the services of Robert Stevens and his team, for acting as the court-appointed receiver for the Company and its predecessor and affiliated entities and pursuant the Merger Agreement, the Company agreed to issue to certain parties as directed by Mr. Stevens shares of Company common stock equal to 90% of the issued and outstanding shares of Company common stock prior to the closing, which will therefore constitute 9% of the issued and outstanding shares of Company common stock immediately following the closing (the “Receiver Shares”).

The Merger Agreement is not subject to a financing condition. The parties have made customary representations, warranties, and covenants in the Merger Agreement. The Merger Agreement also contains a customary “no-shop” covenant prohibiting the Company from soliciting proposals for alternative acquisition or providing information or participating in any discussions in connection with any such proposals.

The Merger is intended to be a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), and the Merger Agreement is intended to be a “plan of reorganization” within the meaning of the regulations promulgated under Section 368(a) of the Code and for the purpose of qualifying as a tax-free transaction for federal income tax purposes.

Further, pursuant to the Amendment, HSH agreed to pay the costs and expenses of the Company resulting from the Company’s engagement of professional service providers, including, but not limited to, those of the transfer agent, legal counsel and auditors, until the earlier of the closing or the termination of the Merger Agreement.

Further, pursuant to the Amendment, the parties acknowledged that the Company and HSH are represented by the same legal counsel and that counsel has advised each of the parties to retain separate counsel to review the terms of the Merger Agreement and the Amendment, and that each party waived such right and waived any related conflicts of interests and confirmed that the parties have previously negotiated the material terms of the Merger Agreement and the Amendment. Further, pursuant to the Amendment, the prior notice person for the Company was removed.

~~Other than the foregoing, no other material changes were made to the Merger Agreement in the Amendment.~~

The foregoing description of the Merger Agreement and the Amendment, and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by the Merger Agreement, and the Amendment, copies of which are as Exhibit 2.1 and 2.2 to this AnnualTransition Report on Form 10-K ~~and incorporated herein by reference.~~

~~As of~~for the ~~date of this Annual Report the Merger has not been consummated; and neither HSH nor the Company has exercised its termination rights. The Company is currently in discussions with HSH~~three-month transition period from June 30, 2020 to ~~extend the date provided to consummate the Merger Agreement from~~ September 30, 2020 ~~to a later date, however there can be no assurances that such discussions will be successful. The Company believes the Merger will be consummated, however, there can be no assurances.~~on January 20, 2021.

In February 2016, all of the Company’s officers and directors resigned, and the Company stopped substantially all operating activities. Since such time, and currently, the Company is a “shell company,” as such term is defined in Rule 12b-2 under the Exchange Act. The Company has not recorded any revenue since 2016. Since May 16, 2016, through the date of this Annual Report, the Company has been operating under the direction of the Receiver.

Operating expenses for the year ended June 30, 2020 totaled $7,163, compared to $17,812 for the same period in 2019. The decrease is attributable to lower professional fees in 2019. Cash flows used in operating activities for the year ended June 30, 2020 totaled $27 compared to $4,846 in 2019. The difference is related in part to the difference in accounts payable from 2020 to 2019.

The Company is currently in receivership. The Company’s financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. At June 30, 2020, the Company had a retained deficit of $13,075,376 and negative working capital of $4,384,704. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s continuation as a going concern is solely dependent upon the Receiver’s ability to raise financing from third parties. There is no assurance that the Company will be successful in doing so.

On March 11, 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic which ~~continues~~continued to spread throughout the U.S. and the globe. In addition to the devastating effects on human life, the pandemic is ~~having~~continuing to have a negative ripple effect on the global economy, leading to disruptions and volatility in the global financial markets. Most U.S. states and many countries have issued policies intended to stop or slow the further spread of the disease such as issuing temporary Executive Orders that, among other stipulations, effectively prohibit in-person work activities for most industries and businesses, having the effect of suspending or severely curtailing operations. COVID-19 and the U.S’s response to the pandemic are significantly affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as a result, the ultimate effect of the pandemic is highly uncertain and subject to change. COVID-19 has already hindered or slowed many of HSH’s businesses, including but not limited to our growth and growth strategies, developments in the marketplace for products, therapies and services, financial results, research and development strategy, regulatory approvals, and competitive strengths. The direct or indirect impact of COVID-19 on our business, results of operations and/or financial condition, continues today, but HSH has thus far weathered the pandemic storm and continues to seek to improve our level of service and patient care. The extent of the ultimate impact of the pandemic on the Company’s operational and financial performance will depend on various developments, including the duration and continued spread of the outbreak, which cannot be reasonably predicted at this time. Accordingly, while management reasonably expects the COVID-19 outbreak to negatively impact the Company, the related consequences and duration are highly uncertain and cannot be predicted at this time.

Comparison of Results of Operations for the Years Ended September 30, 2021 and 2020

For the year ended September 30, 2021, we recorded $9,248,784 in revenue compared to $3,524,334 for the year ended September 30, 2020. The increase is attributable to the establishment and opening of new locations. Included in revenue was $682,500 in related party revenue. The related party revenue was generated from the sale of medical services such as laboratory, durable medical equipment, and pharmacy services through preestablish sales channels that were accessed through the founders of the company.

Cost of sales for the year ended September 30, 2021 was $2,464,189 compared to $2,595,860 in the year ended September 30, 2020. The increase is attributable to the establishment of a new location. Included in cost of sales in September 30, 2022 and 2021 is $2,297,455 and $2,595,860, respectively in cost of goods sold, related parties. The Company is entering into a significant business growth stage and to be prepared for this expansion requires the development of significant infrastructure which was provided through certain founders and corporate officers.

Operating expenses for the year ended September 30, 2021 were $9,438,982 compared to $3,952,621 for the year ended September 30, 2020, an increase of $5,486,361. The increase in operating expenses in the 2021 period compared to 2020 is attributable to an increase of approximately $1,843,000 in administrative expenses and increase of approximately $4,013,000 in contractors expenses related party, offset by a decrease of approximately $370,000 of contractor expenses. The increase of $4,013,000 in contractors expenses related party is attributable to an increase in our labor costs in anticipation of generated higher revenues and the opening of additional location. The key components of general and administrative expenses are the transition expenses of the Company from the planning and development stage to transitioning into the operation of our medical facilities.

~~At June~~As of September 30, ~~2020, our liquid assets consisted~~2021, we had $659,194 in cash and cash equivalents compared to $841,349 as of ~~cash of $211.~~September 30, 2020.

Net cash used in operating activities for year ended September 30, 2021 was $3,575,737 compared to net cash used in operating activities of $3,132,491 for the year ended September 30, 2020. The ~~following tables set forth the components~~increase in cash used in operating activities of ~~the Company’s debt as of June 30, 2020, and June 30, 2019:~~$443,246 is primarily attributable to an increase in accounts receivable balances offset to a lesser extent by other balance sheet changes.

Net cash used in investing activities was $1,323,696 for the year ended September 30, 2021 compared to $554,335 used in investing activities for the year ended September 30, 2020. The increase in 2021 is primarily attributable to an increase in equipment purchases

Net cash provided by financing activities for the year ended September 30, 2021 was $4,717,278 compared to $4,119,278 for the year ended September 30, 2020. The ~~notes payable and the~~increase in 2021 is primarily attributable to an increase in notes payable related parties ~~are unsecured and due to a former director and officer~~ of the Company. As a result of the court order in Nevada in March 2018, no interest can be accrued on this debt. In February 2018, the Company obtained a Receiver’s Certificate for $65,000 which accrues interest at a rate of 10%.

As of June 30, 2020, there was $15,261 in accrued interest due and payable on the Receiver Certificate. The Receiver expects to discharge the notes payable and notes payable related parties with no further liability to the Company, prior to consummating the Merger Agreement. There can be no assurance the Receiver will be successful in discharging this debt.

The Company is under the control of the court-appointed Receiver who is considered a related party. During the year ended June 30, 2020, the Receiver incurred $3,555 in professional fees in managing the Company. Additionally, the Receiver has extended a $65,000 loan to the Company which bears interest at 10%. The Company believes these services and loans are at market rate.approximately $807,000.

We ~~estimate~~will have significant ongoing needs for working capital to fund operations and to continue to expand our operations. To that end, we ~~will need approximately $100,000~~would be required to ~~$150,000 to fully effectuate our business development plans, including to close the Merger as contemplated by the Merger Agreement. There~~raise additional funds through equity or debt financing. However, there can be no assurance that ~~the Merger can occur as planner, or at all. Further,~~ we are subject to the continued impact of COVID-19, as further discussed above. We are dependent on capital raised from third parties to fund our operating expenses. We cannot assure that additional funding will be ~~available on a timely basis, on terms acceptable to us, or at all. We currently have no agreement with any third party to provide us this~~successful in securing additional ~~financing and there can be no assurances that we will obtain this financing, either debt or equity or both,~~capital on favorable terms, orif at all. Currently all of our financing is being provided by interest free demand notes payable from related parties. There are no assurance that these related parties will continue to finance the Company. Our inability to ~~receive additional financing may have a significant negative impact on~~raise capital could require us to significantly curtail or terminate our ~~continued development and results of our operations. COVID-19 has also caused significant disruptions to the global~~operations altogether.

The financial ~~markets, which impacts our ability to raise additional capital. If~~statements do not include any adjustments that might be necessary if the Company is unable to ~~obtain adequate capital due to the continued spread of COVID-19, or otherwise, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations.~~continue as a going concern.

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or “GAAP.” The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reported period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, and we believe those accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements.

Due to the historical operating losses, the inability to recognize an income tax benefit, and the failure to file tax returns for numerous years, there is no provision for current or deferred federal or state income taxes for the period from inception through the period ended June 30, 2020. As of June 30, 2020, the Company had a retained earnings deficit of $13,075,376, however, the amount of that loss that could be carried forward to offset future taxes is indeterminable.

The financial statements required by this Item 8 are included elsewhere in Annual Report on Form 10-K beginning on page F-1.

On August 24, 2020, the Company dismissed BMKR, LLP (“BMKR”) as its independent registered public accounting firm engaged to audit the Company’s financial statements. BMKR’s dismissal was approved by the Company’s receiver, acting under judicial order on behalf of the Company on August 24, 2020.

BMKR had served as the Company’s independent auditors since the 2018 calendar year. BMKR’s reports on the Company’s financial statements for the fiscal years ended June 30, 2019 and 2018, did not contain any adverse opinions or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that such reports included explanatory paragraphs with respect to the Company’s ability to continue as a going concern.

During the fiscal years ended June 30, 2019 and 2018, respectively, and through August 24, 2020, there were no (a) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K) with BMKR on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to BMKR’s satisfaction, would have caused BMKR to make reference to the subject matter thereof in connection with its reports for such years; or (b) reportable events, as described under Item 304(a)(1)(v) of Regulation S-K.

The Company provided BMKR with a copy of the disclosures it ~~is making~~made in ~~this~~its Current Report on Form 8-K disclosing the auditor change filed with the SEC on August 28, 2020 and requested that BMKR provide a letter addressed to the Securities and Exchange Commission indicating whether it agrees with such disclosures. A copy of BMKR’s letter, dated August 24, 2020, was filed as Exhibit 16.1 to the Company’s Form 8-K reporting the auditor change filed with the SEC on August 28, 2020.

Effective as of August 24, 2020, the Company engaged BF Borgers CPA PC (“Borgers”) as the Company’s independent registered public accounting firm for the fiscal year ended June 30, 2020.

During the fiscal years ended June 30, 2019 and 2018 and through August 24, 2020, neither the Company nor anyone on its behalf has consulted with Borgers regarding either (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided nor oral advice was provided to the Company that Borgers concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (b) any matter that was either the subject of a disagreement (as defined in paragraph 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a reportable event (as described in paragraph 304(a)(1)(v)) of Regulation S-K).

We carried out an evaluation as required by paragraph (b) of Rule 13a-15 and 15d-15 of the Exchange Act, under the supervision and with the participation of the ~~Receiver,~~Company’s Interim Chief Executive Officer and Interim Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of ~~June~~September 30, ~~2020.~~2021. Based upon that evaluation, our ~~receiver~~Interim Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of ~~June~~September 30, ~~2020.~~2021.

Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. As of ~~June~~September 30, ~~2020, management~~2021management has not completed an effective assessment of the Company’s internal control over financial reporting based on the 2013 Committee of Sponsoring Organizations (COSO) framework.

Management has concluded that as of ~~June~~September 30, ~~2020,~~2021, our internal control over financial reporting was not effective to detect the inappropriate application of U.S. GAAP.

Management identified the following material weaknesses set forth below in our internal control over financial reporting:

A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Management necessarily applied its judgment in assessing the benefits of controls relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.

~~There~~Other than the officer and director changes in connection with the Merger described elsewhere in this Annual Report on Form 10-K, there have been no changes in our internal control over financial reporting that occurred during the year ended ~~June~~September 30, ~~2020~~2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

The following table sets forth the name and position of our current executive officers and directors.

Justin Smith. On April 15, 2021, Justin Smith was appointed as the Company’s ~~officers resigned,~~Interim Chief Executive Officer, Interim Chief Financial Officer and as the Executive Chairman and member of the Board of Directors of the Company. Justin Smith is a professional investment advisor for institutional clients attempting to navigate the ever-changing global financial markets. Mr. Smith graduated from John Carroll University with a Degree in Marketing Logistics and a Minor in Economics in 2004. After college, he continued to further his education by taking graduate classes while he was employed as the Assistant Director of Marketing at the telecommunications firm Broadvox. Mr. Smith was at Broadvox from January 2015 to June 2016. After leaving the private sector, Mr. Smith became a legislative assistant for the 11th Congressional District, Ohio, working in the office of the Honorable Stefanie Tubbs Jones. After leaving Congress, Mr. Smith began to work on the finance department at the Cuyahoga Metropolitan Housing Authority. From there he began a boutique firm that specialized in open-ended fund investments called the Landes Capital Group in January of 2017 where he still remains an executive to date. Currently he is the President of Landes and Compagnie Trust Prive, a Swedish asset management firm. The firm is a leading provider of independent advisory services for capital projects, including leadership in the early master planning and budgeting phase, identifying, and negotiating the services of the many professionals involved, and proactive guidance in the incorporation of responsible sustainability initiatives. He specializes in working with clients who seek a partner who can advise them through the entire lifecycle of a capital project, particularly those without the in-house resources to devote to such an undertaking. From October 1, 2017 to the present, he serves as the Executive Chairman and Director of HSH.

Jonathan Loutzenhiser. On April 15, 2021, Jonathan Loutzenhiser was appointed as Executive Vice President of the Company and a member of the Board of Directors of the Company. From 2013 to 2014 Mr. Loutzenhiser worked as a sports agent at Recruiting. From 2015 to 2016, Mr. Loutzenhiser served as the Chief Executive Officer at Mediplex. From 2016 to 2017, Mr. Loutzenhiser was the President of IneedMD. He serves es as the Executive Vice President of HSH and a member of the Board of Directors of HSH since he was appointed to such positions on October 1, 2017 and holds this position to date. Mr. Loutzenhiser graduated from Grace University with a degree in business management in 2012.

Dr. Joseph Asuncion. On April 15, 2021, Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company’s Chief Medical Officer. Dr. Asuncion has been serving and remains a Director of HSH since he was appointed to that position on November 7, 2019. Dr. Asuncion attended the University of Maryland where he received his BS in Biology, then received his Doctorate of Medicine at the Perpetual Help College of Medicine in the Philippines. From 2015 to 2017, Dr. Asuncion served as a director on the Board of Directors of IneedMD. From 2010 to 2020 Dr. Asuncion was a director and staff physician at Meritus Family Practice. He has dedicated himself to the practice of medicine for over 20 years. He believes in giving quality and compassionate care to patients and their families. He has also served in numerous leadership roles, which have contributed to the improvement of healthcare in his community. He also has a passionate interest in the development and clinical integration of new medications and technologies. His certifications include Diplomate of the American Academy of Family Medicine and Basic/Advanced Cardiac Life Support Provider.

Dr. Charles Balaban. On April 15, 2021, Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company. Dr. Balaban was appointed as a Director of HSH on October 1, 2017 and serves in this capacity to date. Dr. Balaban received his D.D.S. in dentistry from the University of Toronto in 1973. Since 2015, Dr. Balaban has worked as the owner and operator of a multi-practitioner dental/surgical clinic. Dr. Balaban has been the principal of numerus rollup and M&A transaction in the dental/surgical industry dating back 25 years. He is also a serial entrepreneur and active investor in the medical device industry.

Dr. Sadeem Mahmood. On April 15, 2021, Dr. Sadeem Mahmood was appointed as the Company’s Chief of Surgery. Interventional Cardiologist Sadeem Mahmood, M.D. earned his medical degree at Dow Medical College, University of Karachi, Pakistan. He completed his residency in Internal Medicine at the University of Medicine and Dentistry of New Jersey. He completed fellowships in Cardiology and Nuclear Cardiology at Vanderbilt University Medical Center in Nashville, TN. He is board-certified in Internal Medicine, Cardiovascular Medicine, Interventional Cardiology, and Nuclear Cardiology. Dr. Mahmood previously sat on the Board of Cardiovascular Group for St. Vincent’s Hospital for a total of seven years; he is a fellow of the American College of Cardiology and is a member of the American Society of Medicine and the ~~Company stopped substantially all operating activities. Currently, our Company does not have any officers or directors.~~Arkansas Society of Medicine. Dr. Mahmood has served as a Board Certified Cardiologist at SARC, Inc. since January 2015 to the present. His true passion is his work; the joy he receives from helping his patients is the fuel that keeps him going.

~~Since May 16, 2016, through~~Dr. Richard C. Muckerman II. On April 15, 2021, Dr. Richard Muckerman was appointed as the ~~date~~Company’s Vice President of ~~this Annual Report,~~Strategy and Business Development. Dr. Muckerman was appointed interim Chief Medical Officer and National Director of Promotions and Development HSH on September 31, 2020. Dr. Muckerman attended Georgetown University where he received a B.S. in biology and then Georgetown University School of Medicine for his MD degree. He completed his residency in Obstetrics & Gynecology at Saint John’s Mercy Medical Center in St. Louis which is one of the ~~Company~~largest obstetrics hospitals in the Midwest. He is Board Certified in Obstetrics and Gynecology and is a long-standing Fellow of the American College of Obstetricians and Gynecologists - FACOG. Dr. Muckerman joined his father in the practice of obstetrics and gynecology in 1981. He has maintained an active OB/GYN private practice at St. Louis Women’s Healthcare Group since 2016. Dr. Muckerman incorporated medical genetics into his OB/GYN practice in order to provide personalized preventive healthcare for his patients. He received Genomics certification from the American College of Obstetricians & Gynecologists in 2018. In collaboration with a nationally renowned genetics lab, Dr. Muckerman has developed and implemented Hereditary Cancer Risk Assessment (HCRA) and Breast Cancer Risk Assessment (BCRA) programs in many medical facilities in the St. Louis area: Medical Practices, Breast Centers, and Hospital Systems. Dr. Muckerman has been ~~operating under~~instrumental in organizing and developing ancillary services for private independent physician practices in St. Louis; in 2004, Dr. Muckerman was the ~~direction~~Founding Physician and Medical Director of St. Louis Women’s Surgery Center which was the first women’s-only surgery center in the Midwest. Several years later he recognized the opportunity for the addition of G.I. ancillary services and the Women’s Colonoscopy Center was developed within the Women’s Surgery Center. In 2010, Dr. Muckerman was the Founding Physician and Medical Director of St. Louis Breast Center. It is the only physician owned breast imaging facility in St. Louis. Dr. Muckerman has incorporated a hereditary cancer risk assessment and breast cancer risk assessment program in the breast center. Since 2018, every breast imaging patient has been offered a comprehensive hereditary cancer risk assessment.

Blake Moorman. On April 15, 2021, Blake Moorman was appointed as the Company’s Vice President of Operations. Mr. Moorman was appointed Vice President of HSH on August 1, 2020. Mr. Moorman is an accomplished healthcare industry executive with 15+ years’ experience driving profitability and market share for both large publicly traded healthcare companies as well as several startups. In partnership with the executive management team of HSH, Blake creates leading-edge customer support solutions in support of the ~~Receiver, Robert Stevens.~~organization’s mission and goal of providing best-in-class products and services for healthcare providers across the US. Blake has also held a number of increasingly responsible roles in executive and general management. As a strategist and accessible leader, Blake is known for driving growth and profitability with an expertise in developing and delivering therapeutic solutions for healthcare providers, laboratories, pharmacies, and healthcare companies. Mr. Moorman earned a degree in Engineering from Texas Tech University and previously worked at Depuy Orthopedics for 2004-2013. He then was a minority partner at Pharmetrics Specialty Pharmacy which was acquired in 2015. Blake started Strategic Specialty Solutions in 2013 which grew to one of the largest pharmacy networks in the US and he ceased his positions at same in 2019.

Dr. Richard F. Wittock III, DPM, FACFAS. On April 15, 2021, Dr. Richard F. Wittock was appointed as the Company’s Vice President of Clinical Affairs. Dr. Wittock was appointed Vice President and Chief of Podiatry of HSH on September 31, 2020. From June 2009 to April 2021, Dr. Wittock served as the President, owner and a physician at his own podiatry practice. Dr. Wittock is a native of Michigan and alumnus of Michigan Technological University. He received his doctorate from Barry University in Miami, FL, and earned Magna Cum Laude honors in both his undergraduate and doctoral degrees. His post-doctoral training included a 3-year surgical residency at the Detroit Medical Center at Wayne State University in Detroit, Michigan. He also completed a traumatology fellowship in Mainz, Germany and an external fixation fellowship in Kurgan, Russia. Dr. Wittock specializes in the following procedures: Athletic Injuries - Dr. Wittock played college football and has served as a team podiatrist for a Texas high school; External Fixation; Ankle Implants - Dr. Wittock is authorized by Depuy Orthopedics and Tornier to implant the Agility LP and Saito Talaris ankle implants.

We do not have a standing ~~nominating,~~ compensation, audit or ~~audit~~nominating committee. Rather, ~~our Receiver, acting under judicial order on behalf of~~ the board of directors ~~performs~~perform the functions of these committees. We do not believe it is necessary for our board of directors to appoint such committees at this time because the volume of matters that come before our board of directors for consideration permits the directors to give sufficient time and attention to such matters to be involved in all decision making. Additionally, because our ~~common stock~~Common Stock is not listed for trading or quotation on a national securities exchange, we are not required to have such committees. We plan to form such committees in the future as needed.

We do not have any independent directors, as such term is defined in the listing standards of The NASDAQ Stock Market, at this time. The Company is not quoted on any exchange that requires director independence requirements.

We have not yet adopted a code of ethics that applies to all of our employees, officers, and directors, including those officers responsible for financial reporting. We expect that we will adopt a code of ethics in the near future.

No executive officer, member of the board of directors or control person of our Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

No executive compensation was paid by the Company from February 2016, through the ~~date~~Effective Date of ~~this filing.~~the Merger. In February 2016, all the Company’s officers resigned, and ~~the~~ Company stopped substantially all operating activities. ~~Since May 16, 2016, through~~

The following table summarizes all compensation recorded by us in the ~~date of this Annual Report, the Company has been operating under the direction of the Receiver, Robert Stevens.~~past two fiscal years ended September 30, 2021 for our principal executive officer or other individual serving in a similar capacity.

(1) During the fiscal year ended June 30, 2019, the Receiver incurred $8,838 in professional fees in managing the Company. The Receiver has waived all court approved fees and costs from October 2, 2019 through the closing

(1)

~~(2) During the fiscal year ended June 30, 2020 and prior to October 2, 2019, the Receiver incurred $3,555 in professional fees in managing~~ the Company.

HSH currently only has one employment agreement in place which is with Jonathan Loutzenhiser. HSH and Mr. Loutzenhiser entered into amended and restated employment agreement (the “EA”) on June 1, 2018. Pursuant to the EA, HSH agreed to employ Mr. Loutzenhiser as HSH’s Vice President and Mr. Loutzenhiser agreed to serve in such capacity. The term of the EA is for five (5) years from the entry date. Pursuant to the EA, HSH agreed to compensate Mr. Loutzenhiser with a base salary of $1,200,000 with 50% of same to be accrued until HSH achieves quarterly adjusted EBITDA of $900,000. The EA also includes a bonus to Mr. Loutzenhiser to be determined by HSH’s board of directors. Pursuant to the EA, Mr. Loutzenhiser’s employment can be terminated by HSH for “Cause” or “Good Reason” as such terms are defined in the EA.

We have not adopted any compensation plan to provide for future compensation of any of our directors or executive officers.

The Company has not paid any of its directors in their capacities as such. HSH has not paid any of its directors in their capacities as such. Historically, ~~our~~the Company’s directors have not received compensation for their service. Notwithstanding, at some point in the near future, we plan to adopt a new director compensation program pursuant to which each of our non-employee directors will receive some form of an annual retainer. We plan to reimburse our non-employee directors for reasonable travel expenses incurred in attending board and committee meetings. We also intend to allow our non-employee directors to participate in any equity compensation plans that we adopt in the future.

~~At October 6, 2020,~~As of May 31, 2022, we had ~~127,333,060~~92,214,638 shares of our common stock issued and outstanding. The following table sets forth information regarding the beneficial ownership of our common stock as ~~of October 6, 2020~~May 31, 2022 by:

Unless otherwise indicated, the ~~business~~ address ~~of each person~~for the beneficial owners listed below is ~~in care of~~c/o the Company at ~~387 CORONA ST. SUITE 555, DENVER CO 80218. The~~3 School St, Suite 303, Glen Cove NY 11542.The percentages in the table have been calculated on the basis of treating as outstanding for a particular person, all shares of our common stock outstanding on that date and all shares of our common stock issuable to that holder in the event of exercise of outstanding rights or conversion privileges owned by that person at that date which are exercisable within 60 days of that date. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power may be shared with a spouse.

~~(1) Robert Stevens is currently the Receiver of the Company.~~_____________________

~~(2) Stanley Teeple is the Manager or Next New Deal LLC and has the power to vote and dispose of the shares held by Next New Deal LLC.~~

~~(3) William M. Wright is the President of Take Flight Equities Inc and has the power to vote and dispose of the shares held by Take Flight Equities Inc.~~

(4) Jodi Stevens is the Manager of Thistle Investments LLC and has the power to vote and dispose of the shares held by Thistle Investments LLC. Jodi Stevens is the spouse of the Receiver, Robert Stevens and as such is considered a related party.

(1)	Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares as to which a shareholder has sole or shared voting power or investment power, and also any shares which the shareholder has the right to acquire within 60 days, including upon exercise of common shares purchase options or warrants.
(2)	Based on 92,076,638 shares of the Company’s common stock issued and outstanding as of the date of this Annual Report.
(3)	On April 15, 2021, Justin Smith was appointed as the Company’s Interim Chief Executive Officer, Interim Chief Financial Officer and as the Executive Chairman and member of the Board of Directors of the Company. Justin Smith has voting and dispositive control of 996,520 shares of the Company’s common stock held by Landes And Compagnie Trust Prive KB.
(4)	On April 15, 2021, Dr. Charles Balaban was appointed as a member of the Board of Directors of the Company. Dr. Balaban has voting and dispositive control of 22,514,537 shares of the Company’s common stock held by Black Label Services, Inc.
(5)	On April 15, 2021, Jonathan Loutzenhiser was appointed as Executive Vice President of the Company and a member of the Board of Directors of the Company.
(6)	On April 15, 2021, Dr. Joseph Asuncion was appointed as a member of the Board of Directors of the Company and as the Company’s Chief Medical Officer. Dr. Asuncion has voting and dispositive control of 514,537 shares of the Company’s common stock held by Medical Tech Group Inc.
(7)	On April 15, 2021, Dr. Sadeem Mahmood was appointed as the Company’s Chief of Surgery.
(8)	On April 15, 2021, Dr. Richard F. Wittock was appointed as the Company’s Vice President of Clinical Affairs.
(9)	On April 15, 2021, Dr. Richard Muckerman was appointed as the Company’s Vice President of Strategy and Business Development.
(10)	On April 15, 2021, Blake Moorman was appointed as the Company’s Vice President of Operations.
(11)	Douglas Millar has voting and dispositive control of 22,000,000 shares of the Company’s common stock held by Jackson Hole Medical Advisors, Inc.
(12)	Alex Kozlovski has voting and dispositive control of 9,249,130 shares of the Company’s common stock held by 168 Capital Inc.

We do not have a written policy for the review, approval, or ratification of transactions with related parties or conflicted transactions.

The following includes a summary of transactions since the beginning of the 2019 fiscal year, or any currently proposed transaction, in which HSH or the Company iswere or are to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of their total assets at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

There were notes payable and due to a former director and officer of the Company in the amount of $4,001,267 which were no longer on the books as of March 30, 2021.

The Company was previously under the control of the ~~court appointed~~ Receiver ~~who is~~and the Receiver was considered a related party. During the ~~years~~year ended June 30, ~~2020 and~~ 2019, the Receiver incurred ~~$3,555 and~~ $8,838 in professional fees in managing the Company. Additionally, the Receiver ~~has~~ extended a loan of $65,000 ~~loan~~ to the Company, which ~~bears~~bore interest at 10%. and which was forgiven on April 13, 2021, pursuant to a Loan Forgiveness Agreement.

On August 25, 2020, the parties to the Merger Agreement entered into the Amendment to the Merger Agreement pursuant to which, amongst other things, the Company agreed to issue the Receiver Shares as required by the Merger Agreement in book entry within 10 days of August 25, 2020. The Receiver Shares were issued on August 27, 2020, and consisted of a total of 114,599,754 shares of Company common stock, 38,199,918 of which were issued to Thistle Investments LLC. Jodi Stevens is the Manager of Thistle Investments LLC and has the power to vote and dispose of the shares held by Thistle Investments LLC. Jodi Stevens is the spouse of the Receiver, Robert Stevens and as such iswas considered a related party.

Since the inception of the Company, substantially all of the funding for Company has been provided by related parties that have extended interest free demand loans. These related parties are as follows:

The following table sets forth the fees billed or to be billed to our company for the year ended ~~June~~September 30, ~~2020~~2021, and ~~June~~September 30, ~~2019~~2020 for professional services rendered by ~~BMKR, LLP~~ our ~~former independent registered public accounting firm. Our current~~ independent registered public accounting firm BF Borgers CPA PC was engaged by us effective as of August 24, ~~2020, and therefore there were no professional services rendered by it during the fiscal year ended June 30,~~ 2020.

Fees	2020		2019		2021		2020
Audit Fees	$	2,611	$	19,275	$	80,000	$	60,000
Audit-Related Fees		-		-		-		-
Tax Fees		-		-		-		-
Other Fees		-		-		-		-
Total Fees	$	2,611	$	19,275	$	80,000	$	60,000

Audit fees to ~~BMKR, LLP~~BF Borgers CPA PC were for professional services rendered for the audit of our annual financial statements for the ~~year~~years ended ~~June~~September 30, ~~2019.~~2021, and 2020.

During 2021 and 2020, ~~and 2019, BMKR, LLP~~BF Borgers CPA PC did not provide any assurance and related services that are reasonably related to the performance of the audit or review or our financial statements that are not reported under the caption “Audit Fees” above.

As ~~BMKR, LLP~~BF Borgers CPA PC did not provide any services to us for tax compliance, tax advice and tax planning during ~~2020~~2021 and ~~2019,~~2020, no tax fees were billed or paid during those fiscal years.

~~BMKR, LLP~~BF Borgers CPA PC did not provide any products and services not disclosed in the table above during ~~2020~~2021 and ~~2019.~~2020. As a result, there were no other fees billed or paid during ~~2020~~2021 and ~~2019.~~

To the shareholders and the board of directors of Healthcare Solutions Management Group, Inc.

We have audited the accompanying consolidated balance ~~sheet~~sheets of Healthcare Solutions Management Group, Inc. (the "Company") as of ~~June~~September 30, 2021 and September 30, 2020, the related ~~statement~~statements of operations, stockholders' equity (deficit), and cash flows for the ~~year~~years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of ~~June~~September 30, 2021 and September 30, 2020, and the results of its operations and its cash flows for the ~~year~~years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s minimal activities raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

~~Substantial Doubt about the Company’s Ability to Continue as a Going Concern~~

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We have audited the accompanying consolidated balance sheet of Healthcare Solutions Management Group, Inc. ( Formerly Verity Corp.) (the Company) as of June 30, 2019 and the related consolidated statement of operations, consolidated stockholders' equity, and cash flows for the year ended June 30, 2019, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company as of June 30, 2019, and the results of its operations and its cash flows for the year ended June 30, 2019 , in conformity with accounting principles generally accepted in the United States of America.

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the financial statements, the Company had a deficit net worth of $4,386,083 during the year ended June 30, 2019. The Company is in arrears with certain vendor creditors which, among other things, cause the balances to become due on demand. The Company is not aware of any alternate sources of capital to meet such demands, if made.

As discussed in Note 3 to the financial statements, the Company’s significant deficit net worth raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.

~~The accompanying notes are an integral part of the consolidated financial statements.~~

The accompanying notes are an integral part of ~~the~~these consolidated financial statements.

~~The accompanying notes are an integral part of the consolidated financial statements.~~

Healthcare Solutions Management Group, Inc. (“the “Company”) f/k/a Verity Corporation is the parent of Verity Farms II, Inc. (“Verity Farms II”) and Aistiva Corporation (“Aistiva”) (f/k/a AquaLiv, Inc.). Verity Farms II was dedicated to providing consumers with safe, high-quality and nutritious food sources through sustainable crop and livestock production. Aistiva has released products in the industries of water treatment, skincare, and agriculture. Aistiva was primarily known for the AquaLiv Water System product which also produces the majority of its revenue and blends well with the Verity Water systems.

~~In February 2016, all the Company’s officers resigned, and Company stopped substantially all operating activities. On May 16, 2016, pursuant to Case Number A-16-733815-B, Nevada’s 8~~^th Judicial District, Business Court, appointed Robert Stevens as Receiver (“Receiver”) for Verity Corp. on May 3, 2016. Creditors were required to provide claims in writing under oath on or before November 3, 2016, or they will be barred under NRS §78.675”. Since May 16, 2016, through the date of this report, the Company has been operating under the direction of the Receiver

On March 22, 2018, the Nevada Court approved a plan of reorganization that involved authorizing the cancellation of all preferred shares of Verity Corp, the cancellation of certain insider shares, a reverse stock split up to a maximum of 200-1, and a reorganization that would place the liquidation of Verity Corp’s assets under a liquidating trustee while maintaining the public, purchasers for value with equity in the surviving entity. Once the reorganization is completed the Receiver will be discharged.

~~On June 14, 2019,~~ Healthcare Solutions Management Group, Inc., a Delaware corporation, and successor in interest to Verity Delaware Inc., a Delaware corporation which was previously a Nevada corporation named Verity Corp. ~~(the~~(“we,” “us, “our” or the “Company”) was incorporated on April 11, 2006 in the state of Nevada under the name Infrared Systems, International.

On April 1, 2013, the Company changed its name from AquaLiv Technologies Inc. to Verity Corp. and our stock symbol changed to VRTY.

In February 2016, all of the Company’s officers and directors resigned, and the Company stopped substantially all operating activities. At such time, the Company became a “shell company,” as such term is defined in Rule 12b-2 under the Exchange Act.

On June 14, 2019, the Company entered into a Merger Agreement (the “Merger Agreement”) by and between the Company, Verity Merger Corp., a wholly-owned subsidiary of the Company ~~(“Merger~~and a Delaware corporation (the “Merger Sub”), and Healthcare Solutions Holdings, Inc., a Delaware corporation (“HSH”). Pursuant to the terms of the Merger Agreement, the parties agreed that Merger Sub would merge with and into HSH, with HSH being the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Merger”).

The ~~closing~~Merger closed on April 15, 2021 (the “Closing”), at which time Merger Sub merged with and into HSH with HSH being the surviving entity, and HSH became our wholly owned subsidiary. As a result of the consummation of the Merger, ~~will take place on~~HSH became our wholly owned subsidiary and the ~~third~~ business ~~day following~~of HSH became the ~~satisfaction or waiver (by the party for whose benefit the condition exists)~~business of the ~~closing conditions~~Company going forward. HSH is an integrated healthcare company which strives to provide vital services and a high-quality of care for patients over the course of their lifetime. HSH was organized with the goal of becoming an advanced, national healthcare system in the United States, providing clinicians with state-of-the-art diagnostic and therapeutic tools, and providing patients with greater access to a higher level of care in local communities that it believes have historically been underserved by the medical industry. HSH currently conducts directly through HSH, and in the near future intends to, conduct various, distinct operations through its to be formed wholly owned operating subsidiaries, within the medical industry, seeking to serve the needs of patients’ and physicians alike.

~~Upon effectiveness~~Receiver, were issued an aggregate total of the Merger, (i) HSH’s certificate of incorporation will be the certificate of incorporation of the surviving company, and (ii) HSH’s bylaws will be the bylaws of the surviving company. In addition, upon the effectiveness of the Merger, HSH’s directors immediately prior to effectiveness of the Merger will be the directors of the surviving corporation. Accordingly, at the Closing, the Company’s current sole director will elect Justin Smith, Jonathan Loutzenhiser and Dr. Charles Balaban as members114,599,754 shares of the Company’s ~~board of directors, and then~~common stock. At Closing, the ~~current sole director shall resign. Also, upon effectiveness of the~~aggregate Merger ~~HSH’s officers immediately prior to effectiveness of the Merger will be the directors of the surviving company.~~

~~The aggregate merger~~ consideration ~~to be~~ paid to the holders of the HSH common ~~stock in the merger will be an aggregate number of~~was 1,145,997,555 shares of the Company’s common stock constituting 90% of the issued and outstanding shares of Company common stock immediately following the Closing, assuming issuance of the Receiver Shares (as hereinafter defined). At the effective time of the Merger, each share of HSH common stock issued and outstanding immediately prior to the effective time (other than shares canceled as provided in the Merger Agreement, if any), will be converted into shares of Company common stock, at an exchange rate as required to cause the number of shares of Company common stock issued to the holders of the HSH common stock to be 90% of the issued and outstanding shares of the Company common stock immediately following the Closing, assuming issuance of the Receiver Shares, which is currently expected to result in an exchange ratio of 127.33306 shares of Company common stock per share of HSH common stock (as ultimately so determined, the “Exchange Ratio”), with any fractional shares of Company common stock being rounded to the nearest whole share of Company common stock. The Exchange Ratio will be finally determined by the parties to the Merger Agreement prior to the Closing.

As ~~consideration for~~a result of the ~~services~~consummation of ~~Robert Stevens~~the Merger, on April 15, 2021, HSH became our wholly owned subsidiary and ~~his team, who has acted as~~ the ~~court-appointed receiver for~~business of HSH became the business of the Company ~~and its predecessor and affiliated entities, in the Merger Agreement the Company agreed that, immediately prior to~~going forward. Accordingly, at the Closing, the Company will issue to certain parties as directed by Mr. Stevens a total number of shares of Company common stock equal to 90% of the issued and outstanding shares of Company common stock immediately prior to the Closing, which will therefore constitute 9% of the issued and outstanding shares of Company common stock immediately following the Closing (the “Receiver Shares”). The Receiver Shares were issued on August 27, 2020 and consisted of a total of 114,599,754 shares of Company common stock.

~~The completion of the Merger is subject to certain customary closing conditions, including that HSH will have provided to the Company HSH’s audited and unaudited financial statements as required~~ceased to be ~~included in the Company’s filings with the Securities and Exchange Commission.~~

~~The Merger Agreement is not subject to~~ a financing condition. The parties have made customary representations, warranties, and covenants in the Merger Agreement. The Merger Agreement also contains a customary “no-shop” covenant prohibiting the Company from soliciting proposals for alternative acquisition or providing information or participating in any discussions in connection with any such proposals.shell company as of April 15, 2021.

The Merger was accounted for as a reverse merger and HSH is ~~intended~~considered the acquirer for accounting and financial reporting purposes.

The Company was previously in receivership. On May 16, 2016, pursuant to ~~be a reorganization within~~Case Number A16-733815-B, Nevada’s 8th Judicial District, Business Court, appointed Robert Stevens as receiver (the “Receiver”) for the ~~meaning of Section 368(a)~~Company. Creditors of the ~~Internal Revenue Code~~Company were required to provide claims in writing under oath on or before November 3, 2016, or they would be barred under Nevada Revised Statute §78.675. Since May 16, 2016, through the date of ~~1986, as amended (the “Code”),~~the Merger, the Company was operating under the direction of the Receiver. On March 5, 2018, the District Court in Clark County, Nevada approved a plan of reorganization for the Company and the ~~Merger Agreement is intended to be a “plan of reorganization” within the meaning~~discharge of the ~~regulations promulgated~~Receiver upon completion of his duties under ~~Section 368(a)~~the court order. Upon the Closing of the ~~Code~~Merger, the reorganization of the Company described in the court order was completed and, ~~for the purpose of qualifying~~ as a ~~tax-free transaction for federal income tax purposes.~~result and pursuant to the court order dated March 5, 2018, the Receiver was automatically discharged and the receivership was automatically terminated such that no further action was needed by the Receiver or the Company in connection with the receivership, and such that Company was no longer in receivership.

The Merger Agreement contains certain termination rights that may be exercised by the Company or HSH, as applicable, including in the event that (i) both parties agree by mutual written consent to terminate the Merger Agreement, (ii) the Merger is not consummated by July 30, 2019, or (iii) any law or order permanently restraining, enjoining or otherwise prohibiting consummation of the Merger having become final and non-appealable.

As of the date of this Report the Merger has not been consummated; and neither HSH nor the Company has exercised its termination rights. The Company is currently in discussions with HSH to extend the date provided to consummate the Merger Agreement from September 30, 2020 to a later date, however there can be no assurances that such discussions will be successful. The Company believes the Merger will be consummated, however, there can be no assurances.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. On a consolidated basis, the Company has incurred significant operating losses since inception.

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, notes payable and related party loans as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans in order to fund its operations.

The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) under the accrual basis of accounting.

On September 13, 2021, the Board of Directors of the Company approved a 1 for 115 Reverse Stock Split of the Company’s common stock with any fractional shares of common stock resulting therefrom being rounded up to the nearest whole share of common stock. All share amounts referenced in this Report have been retroactively adjusted to reflect the reverse stock split for all periods presented, unless specifically stated otherwise.

Certain prior period amounts have been reclassified to conform with the current period presentation.

In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, as well as the reported amounts of expenses during the reporting periods. These accounts and estimates include, but are not limited to ~~the valuation of accounts receivables, and~~ liabilities and ~~the estimation on useful lives of property, and plant and equipment.~~tax provisions. Actual results could differ from these estimates.

The consolidated financial statements include the financial statements of the Company and its ~~subsidiaries.~~

subsidiary. All significant inter-company balances and transactions within the Company and subsidiaries have been eliminated upon consolidation.

Cash and cash equivalents are carried at cost and represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by actively pursuing past due accounts. An allowance for doubtful accounts is established and determined based on managements’ assessment of the accounts receivables collectibles. Judgment is required in assessing the amount of the allowance. The Company considers the historical level of credit losses and applies percentages to different receivables categories. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a larger allowance may be required.

The Company derives revenues from the sale of agricultural products, animal feeds, consulting services, and various water units. The Company’s sales arrangements are not subject to warranty. On July 1, 2018, we adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after July 1, 2018, are presented under ASC 606, while prior period amounts were reported in accordance with our historic accounting under ASC 605. The Company has not recorded any revenue since 2016 so the transition to ASC 606 had no impact on our financial statements.

~~Cost of goods sold consists primarily of material costs which are directly attributable to the manufacture of products, to the products held for resale and to the provision of services.~~

Service income is generated from the resale of 3^rd party services into physician offices. Operating income is generated directly from physicians and other entities in the medical business for providing management services for them.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provided in Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”) requires entities to use a five-step model to recognize revenue by allocating the consideration from contracts to performance obligations on a relative standalone selling price basis. Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. ASC 606 also includes Subtopic 340-40, Other Assets and Deferred Costs – Contracts with Customers, which requires the deferral of incremental costs of obtaining a contract with a customer. This new guidance was initially effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016 and early adoption was not permitted. However, in July 2015, the FASB voted to defer the effective date of this ASU by one year for reporting periods beginning after December 15, 2017, with early adoption permitted as of the original effective date. As a result, the effective date for the Company was January 1, 2018.

FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2021 and September 30, 2020. The Company uses the market approach to measure fair value for its Level 1 financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. The respective carrying value of certain balance sheet financial instruments approximates its fair value. These financial instruments include cash, trade receivables, related party payables, accounts payable, accrued liabilities and short-term borrowings. Fair values were estimated to approximate carrying values for these financial instruments since they are short term in nature, and they are receivable or payable on demand.

The estimated fair value of assets and liabilities acquired in business combinations and reporting units and long-lived assets used in the related asset impairment tests utilize inputs classified as Level 3 in the fair value hierarchy.

The Company determines the fair value of contingent consideration based on a probability-weighted discounted cash flow analysis. The fair value remeasurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in the fair value hierarchy. In each period, the Company reassesses its current estimates of performance relative to the stated targets and adjusts the liability to fair value. Any such adjustments are included as a component of Other Income (Expense) in the Consolidated Statements of Operations and Comprehensive Loss.

The Company was initially funded by Landes & Cie Private Trust based out of Sweden. In the U.S. there are certain regulatory requirements for healthcare companies in U.S. to maintain a minimum amount of capital on hand or they are subject to additional rules and regulation. Landes provided enough capital for the company so that all regulatory capital thresh holds are met.

We have identified accounting for marketable investment securities as a critical accounting policy due to the significance of the amounts included in our balance sheet. All of the securities included in investments have quoted market prices and trade actively. The Company’s intention is not to actively trade its investments or to use this investment for working capital. The Company records these investments at their fair value based on quoted market prices with the unrealized gain or loss recorded in accumulated other comprehensive income, a component of stockholders’ equity, net of deferred taxes.

The Company adopts the ASC Topic 740, “Income Taxes “ regarding accounting for uncertainty in income taxes which prescribes the recognition threshold and measurement attributes for financial statement recognition and measurement of tax positions taken or expected to be taken on a tax return. In addition, the guidance requires the determination of whether the benefits of tax positions will be more likely than not sustained upon audit based upon the technical merits of the tax position. For tax positions that are determined to be more likely than not sustained upon audit, a company recognizes the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not determined to be more likely than not sustained upon audit, a company does not recognize any portion of the benefit in the financial statements. The guidance provides for de-recognition, classification, penalties, and interest, accounting in interim periods and disclosure. For the years ended ~~June~~September 30, ~~2020,~~2021, and ~~2019,~~2020, the Company did not have any interest and penalties associated with tax positions. As of ~~June~~September 30, ~~2020,~~2021, and ~~2019,~~September 30, 2020, the Company did not have any significant unrecognized uncertain tax positions.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of income in the period that includes the enactment date. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits or that future deductibility is uncertain.

With the exception of legal fees, substantially all professional fees expensed by the Company subsequent to the appointment of the court-appointed Receiver, represent hours of work performed by him to help the Company emerge from receivership by obtaining external financing. The fees are a liability of the Company and are expensed as incurred.

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20, the Related parties include a). affiliates of the Company; b). entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c). trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d). principal owners of the Company; e). management of the Company; f). other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g). other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include a). the nature of the relationship(s) involved; b). a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c). the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d). amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s consolidated financial position, consolidated results of operations or consolidated cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, consolidated financial position, and consolidated results of operations or consolidated cash flows.

Accounts receivable are customer obligations due under normal trade terms which are recorded at net realizable value. The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required.

Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. If the Company’s actual collection experience changes, revisions to its allowance may be required. After all attempts to collect a receivable have failed, the receivable is written off against the allowance.

The equipment is comprised of ultrasounds, beds, stretchers, cardiac telemetry equipment, cardiac monitors, defibrillators, and other surgical equipment.

Property and equipment are stated at cost or fair value if acquired as part of a business combination. Depreciation is computed by the straight-line method and is charged to operations over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. The carrying amount and accumulated depreciation of assets sold or retired are removed from the accounts in the year of disposal and any resulting gain or loss is included in results of operations. The estimated useful lives of property and equipment are as follows:

As of September 30, 2021 and September 30, 2020 the Company had $1,821,081 and $587,083 in equipment that had not yet been placed in service.

The Company adopted FASB Accounting Standards Codification 855 “Subsequent Events” (“ASC 855”) to establish general standards of accounting for and disclosure of events that occur after the balance sheet date, but before the financial statements are issued or available to be issued.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its consolidated financial condition or the consolidated results of its operations.

The ~~Company is currently in receivership. The~~following table sets forth the components of the Company’s ~~financial statements have been presented~~accounts receivable on September 30, 2021 and September 30, 2020:

For the ~~basis that it is a going concern, which contemplates the realization of assets~~fiscal year ended September 30, 2021 and ~~the satisfaction of liabilities in the normal course of business. On June 30,~~ 2020, the ~~Company had a retained deficit~~were no customers that accounted for more than 10% of $13,075,376 and current liabilities in excess of current assets by $4,384,704. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

The Company’s continuation as a going concern is solely dependent upon the Receiver’s ability to raise financing from third parties. There is no assurance that the Company will be successful in doing so.annual revenue.

As of September ne 30, 2021 and September 30, 2020 the balance of investments was $89,823,346 and $83,087,469 respectively. These investment are comprised of securities that trade frequently with quoted prices. The Company’s intention is not to trade these securities but rather to hold these securities to demonstrate that the Company has enough capital on hand to meet regulatory requirements for certain healthcare companies.

For the fiscal year ended September 30, 2021 the Company recorded an unrealized gains on investments of $5,598,328 compared to a unrealized loss on investments of $1,137,548 for the fiscal year ended September 30, 2020, respectively.

The following tables set forth the components of the Company’s ~~debt~~notes as of ~~June~~September 30, ~~2020,~~2021 and ~~June~~September 30, ~~2019:~~2020

The Notes payable and the real estate loans are unsecured and due to a former director and officer of the Company. As a result of the court order in Nevada in March 2018, no interest can be accrued on this debt. In February 2018, the Company obtained a Receiver’s Note for $65,000 which accrues interest at a rate of 10%. As of June 30, 2020, there was $15,261 in accrued interest due and payable on the Receiver Note. The Receiver expects to discharge the Notes Payable and Real Estate Loans with no further liability to the Company, prior to consummating the Merger Agreement referenced throughout this Report. There can be no assurance the Receiver will be successful in discharging this debt.

The Company is under the control of the court-appointed Receiver who is considered a related party. During the years ended June 30, 2020 and 2019, the Receiver incurred $3,555 and $8,838 in professional fees in managing the Company. Additionally the Receiver has extended a $65,000 loan to the Company which bears interest at 10%. The Company believes these services and loans are at market rate.

On August 25, 2020, the parties to the Merger Agreement entered into amendment no. 1 (the “Amendment”) to the Merger Agreement pursuant to which, amongst other things, the Company agreed to issue the Receiver Shares as required by the Merger Agreement in book entry within 10 days of August 25, 2020. The Receiver Shares were issued on August 27, 2020 and consisted of a total of 114,599,754 shares of Company common stock, 38,199,918 of which were issued to Thistle Investments LLC. The 38,199,918 shares were valued at $0.027 per share, which was the closing price of the Company’s Common stock on August 25, 2020. Jodi Stevens is the Manager of Thistle Investments LLC and has the power to vote and dispose of the shares held by Thistle Investments LLC. Jodi Stevens is the spouse of the Receiver, Robert Stevens and as such is considered a related party.

The Company has ~~1,000,000,000~~1,400,000,000 common shares authorized at a par value of $0.001. As of September 30, 2021, and September 30, 2020 the were 11,072,440 and 1,107,244 common shares outstanding, respectively.

On ~~June 30, 2017,~~September 13, 2021, the Board of Directors of the Company ~~had~~approved a 1 for 115 Reverse Stock Split of the ~~following~~Company’s common stock with any fractional shares of ~~Preferred Stock outstanding:~~common stock resulting therefrom being rounded up to the nearest whole share of common stock

~~Pursuant~~On April 15, 2021 the Company consummated the Merger, whereby 9,965,196 (post-split) shares of the Company’s common stock were issued to ~~a Court order in March 2018, all~~the holders of ~~these preferred shares were canceled, and the amount of outstanding~~HSH common ~~shares were reduced from 17,838,306 shares outstanding as of June 30, 2017, to 12,733,306 shares outstanding as of June 30, 2020, and June 30, 2019.~~stock.

The Company’s principal office is located at 3 School St, Suite 303, Glen Cove, NY 11542, where it leases approximately 2,250 square feet of office space at a monthly rent of $2,500 per month. We believe that these facilities are adequate to support the Company’s existing operations and that we will be able to obtain appropriate additional facilities or alternative facilities on commercially reasonable terms if and when necessary.

Due to the historical operating losses, the inability to recognize an income tax benefit, and the failure to file tax returns for numerous years, there is no provision for current or deferred federal or state income taxes for the period from inception through the period ended ~~June~~September 30, ~~2020.~~2021. As of ~~June~~September 30, ~~2020,~~2021 the Company had a retained earnings deficit of ~~$13,075,376,~~$29,171,161, however, the amount of that loss that could be carried forward to offset future taxes is indeterminable.

In accordance with ASC 855-10 management has performed an evaluation of subsequent events from ~~June~~September 30, ~~2020,~~2021, through the date the financial statements were available to be issued and noted ~~the following item~~in subsequent events requiring ~~disclosure:~~disclosure except as follows:

On August 25, 2020, the parties to the merger agreement entered into amendment no. 1 (the “Amendment”) to the Merger Agreement pursuant to which the date provided to consummate the Merger Agreement was extended from July 30, 2019 to September 30, 2020. Further, pursuant to the Amendment,November 26, 2021, the Company and HSH and HSH’s wholly owned subsidiary HSH Surgical, Inc. (“HSHS”) entered into an Ambulatory Surgery Center Development Agreement (the “Agreement”) with Jameson, LLC DBA American Development Partners, a Tennessee limited liability company (together with its subsidiaries, related parties, successors-in-interests, and affiliates, the “Developer”). The term of the Agreement is ten (10) years from November 26, 2021. Pursuant to the Agreement, the Developer agreed to ~~reasonably cooperate~~use commercially reasonable efforts to ~~terminate~~present HSHS with “Qualified Projects,” as such term is defined in the ~~engagement~~Agreement. During the term of the ~~Company’s prior registered agent in Nevada,~~Agreement, the Developer agreed to present HSHS with ~~the~~ten (10) Qualified Projects per year, HSHS however is not required to accept a Qualified Project. HSHS agreed to enter into one hundred (100) Lease Agreements (the “Tenant Commitment”) with an option for twenty-five (25) additional units with anticipated development costs ~~related thereto~~ to be ~~paid by HSH. Further, pursuant~~approximately fourteen million dollars ($14,000,000) a unit (actual costs will vary based on individual projects) for a total initial commitment of approximately one billion four hundred million dollars ($1,400,000,000) with an option for an additional three hundred and fifty million dollars ($350,000,000); provided that each Lease Agreement relates to a Qualified Project. Pursuant to the ~~Amendment,~~Agreement, the Developer has the exclusive rights to develop single tenant HSH Surgical Ambulatory Surgery Center units on a nationwide basis for HSHS.

On November 26, 2021, the Company, HSH and HSH’s wholly owned subsidiary Advance Care Medical Holdings, Inc. (“ACM”) entered into an Urgent Care Center Development Agreement (the “UC Agreement”) with Jameson, LLC DBA American Development Partners, a Tennessee limited liability company (together with its subsidiaries, related parties, successors-in-interests, and affiliates, the “Developer”). The term of the UC Agreement is ten (10) years from November 26, 2021. Pursuant to the UC Agreement, the Developer agreed to ~~issue~~use commercially reasonable efforts to present ACM with “Qualified Projects,” as such term is defined in the ~~Receiver Shares as~~UC Agreement. During the term of the UC Agreement, the Developer agreed to present ACM with seventy-five (75) Qualified Projects per year, however ACM is not required ~~by the Merger Agreement in book entry within 10 days of August 25, 2020. The Receiver Shares were issued~~to accept a Qualified Project. ACM agreed to enter into five hundred (500) Lease Agreements (the “Tenant Commitment”) with an option for two hundred (200) additional units with anticipated development costs to be approximately four million five hundred thousand dollars ($4,500,000) a unit (actual costs will vary based on ~~August 27, 2020 and consisted of~~individual projects) or a total initial commitment of ~~114,599,754 shares of Company common stock.~~approximately two billion two hundred and fifty million dollars ($2,250,000,000.00) with an option for an additional nine hundred million dollars ($900,000,000); provided that each Lease Agreement relates to a Qualified Project. The developer has the exclusive rights to develop single tenant Advance Care Medical Urgent and Comprehensive Care Center units on a nationwide basis for ACM.

~~(b)~~ The entry into the Agreement and the UC Agreement, triggered the issuance, on December 31, 2021 by the Company of 81,000,000 shares of its common stock to the following parties in the following amounts (the “Shares”).

Additionally, subsequent to September 30, 2021, the Company issued 142,198 shares for consulting services.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Delaware		38-3767357
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~387 Corona St.,~~3 School St, Suite ~~555, Denver, CO~~303, Glen Cove NY		~~80218~~11542
(Address of principal executive offices)		(Zip Code)

Title of each class		Trading Symbol(s)		Name of exchange on which registered
N/A		N/A		N/A

		PAGE NO.
PART I

Item 1.	Business.	43
Item 1A.	Risk Factors.	721
Item 1B.	Unresolved Staff Comments.	1432
Item 2.	Properties.	1432
Item 3.	Legal Proceedings.	1432
Item 4.	Mine Safety Disclosures.	33

PART II

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.	1534
Item 6.	~~Selected Financial Data.~~[Reserved]	1737
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	1738
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	2141
Item 8.	Financial Statements and Supplementary Data.	2241
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.	2241
Item 9A.	Controls and Procedures.	2342
Item 9B.	Other Information.	2343
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.	43

PART III

Item 10.	Directors, Executive Officers and Corporate Governance.	2444
Item 11.	Executive Compensation.	2447
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.	2549
Item 13.	Certain Relationships and Related Transactions, and Director Independence.	2651
Item 14.	Principal Accounting Fees and Services.	2651

PART IV

Item 15.	Exhibits, Financial Statement Schedules.	2752
Item 16.	Form 10-K Summary.	2855
	Signatures.	2956

	·	Gynecology and Women’s Health
	·	Infectious Illnesses
~~Table of Contents~~	·	Pediatric Complaints
	·	Pulmonary Complaints
	·	Wound Care

	·	Laboratory, Pathology, Radiology, Pharmacy, Variety of In-office Ancillary Services;
	·	Evaluate compliance issues and documentation systems & provide operations oversight to suggest areas of improvement;
~~Table of Contents~~	·	Review accounts payable and accounts receivable - revenue cycle and supply chain management; and
	·	Liaison between medical office administrators and service providers.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated ~~filer~~Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

	·	Advance Care Medical Holdings, Inc. is a Delaware, corporation (“ACM”) which seeks to offer a host of comprehensive care service directly to patients;

	·	HSH Surgical, Inc. is a Delaware, corporation (“HSHS”) which seeks to own and operate Ambulatory Surgery Centers; and

	·	HSH Medical Services, Inc. (“HSHMS”) is a Delaware, corporation which seeks to provide ancillary services directly to physician offices and engage in sales and marketing of medical products to doctors.

	·	Allergy and Immunology
	·	Cardiovascular Issues
	·	Endocrine Issues
	·	Eyes, Ears, Nose and Throat
	·	Gastrointestinal Complaints

	·	Cardiac Surgery
	·	Vascular Surgery
	·	Bariatric Surgery
	·	Colon and Rectal Surgery
	·	Endocrine Surgery
	·	General Surgery
	·	Gynecological Surgery
	·	Hand Surgery
	·	Head and Neck Surgery
	·	Hernia Surgery
	·	Neurosurgery
	·	Orthopedic Surgery
	·	Ophthalmological Surgery
	·	Outpatient Surgery
	·	Pediatric Surgery
	·	Plastic and Reconstructive Surgery
	·	Podiatric Surgery
	·	Robotic Surgery (Da Vinci Robotic Surgical System)
	·	Thoracic Surgery
	·	Urologic Surgery

	·	Medical Equipment: examples include but are not limited to back braces with cold therapy, shoulder sling/braces, custom fit full-length knee brace, total joint kit, spine kit, pain patch and others.

	·	Medical Devices: examples include but are not limited to electrocardiogram (ecg) 3 / 6 / 12 / 18 lead units, interpretative ecg units, electroencephalogram (eeg) monitoring equipment, home sleep monitoring equipment, cardiac monitoring equipment and others.

	·	Laboratory Services: examples include but are not limited to molecular testing, pharmacogenomic testing, cancer genetic testing, breast cancer/lynch syndrome/colon, molecular pathology, respiratory testing, pathology testing, wound care testing, urine blood wellness testing and others.

	·	Pharmacy Services- examples include but are not limited to traditional mail order, specialty compounding, 503a/503b opportunities, wholesale, specialty non-opioid, pain, podiatry and others.

	·	Facilities management;
	·	Operational reporting (workflow auditing);
	·	Billing services;
	·	Performance evaluations for staff;

	·	Leverage HSH’s relationships, assets, and experience to develop HGHCs.
	·	Grow HGHCs by utilizing banking relationships to facilitate acquisitions.
	·	Assist to and launch HGHCs to public markets.

•●	difficulties integrating the operations, technologies, services, and personnel of the acquired companies;

•●	challenges maintaining our internal standards, controls, procedures, and policies;

•●	diversion of management’s attention from other business concerns;

•●	over-valuation by us of acquired companies;

•●	litigation resulting from activities of the acquired company, including claims from terminated employees, customers, former stockholders and other third parties;

•●	insufficient revenues to offset increased expenses associated with the acquisitions and unanticipated liabilities of the acquired companies;

•●	insufficient indemnification or security from the selling parties for legal liabilities that we may assume in connection with our acquisitions;

•●	entering markets in which we have no prior experience and may not succeed;

•●	risks associated with foreign acquisitions, such as communication and integration problems resulting from geographic dispersion and language and cultural differences, compliance with foreign laws and regulations and general economic or political conditions in other countries or regions;

•●	potential loss of key employees of the acquired companies; and

•●	impairment of relationships with clients and employees of the acquired companies or our clients and employees as a result of the ~~acquired companies or our clients and employees as a result of the~~ integration of acquired operations and new management personnel.

	·	federal laws, including the federal False Claims Act, which provide for penalties against entities and individuals which knowingly or recklessly make claims to Medicare, Medicaid, and other governmental healthcare programs, as well as third-party payors, which contain or are based upon false or fraudulent information;

	·	a provision of the Social Security Act, commonly referred to as the “Anti-Kickback Statute,” that prohibits the knowing and willful offering, payment, solicitation or receipt of any bribe, kickback, rebate, or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for items and services covered, in or in part, by federal healthcare programs such as Medicare and Medicaid;

	·	a provision of the Social Security Act, commonly referred to as the Stark Law or physician self-referral law, that (subject to limited exceptions) prohibits physicians from referring Medicare patients to an entity for the provision of specific “designated health services” if the physician or a member of such physician’s immediate family has a direct or indirect financial relationship with the entity, and prohibits the entity from billing for services arising out of such prohibited referrals;

	·	a provision of the Social Security Act that provides for criminal penalties on healthcare providers who fail to disclose known overpayments;

	·	a provision of the Social Security Act that provides for civil monetary penalties on healthcare providers who fail to repay known overpayments within 60 days of identification or the date any corresponding cost report was due, if applicable, and also allows improper retention of known overpayments to serve as a basis for False Claims Act violations;

	·	state law provisions pertaining to anti-kickback, self-referral, and false claims issues, which typically are not limited to relationships involving governmental payors;

	·	provisions of, and regulations relating to, the Health Insurance Portability and Accountability Act (“HIPAA”) that provide penalties for knowingly and willfully executing a scheme or artifice to defraud a health-care benefit program or falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services;

	·	provisions of HIPAA and Health Information Technology for Economic and Clinical Health Act (“HITECH”) limiting how covered entities, business associates and business associate sub-contractors may use and disclose PHI and the security measures that must be taken in connection with protecting that information and related systems, as well as similar or more stringent state laws;

	·	federal and state laws that provide penalties for providers for billing and receiving payment from a governmental healthcare program for services unless the services are medically necessary and reasonable, adequately, and accurately documented, and billed using codes that accurately reflect the type and level of services rendered;

	·	federal laws that provide for administrative sanctions, including civil monetary penalties for, among other violations, inappropriate billing of services to federal healthcare programs, payments by hospitals to physicians for reducing or limiting services to Medicare or Medicaid patients, or employing or contracting with individuals or entities who/which are excluded from participation in federal healthcare programs;

	·	federal and state laws and policies that require healthcare providers to enroll in the Medicare and Medicaid programs before submitting any claims for services, to promptly report certain changes in their operations to the agencies that administer these programs, and to re-enroll in these programs when changes in direct or indirect ownership occur or in response to revalidation requests from Medicare and Medicaid;

	·	state laws that prohibit general business entities from practicing medicine, controlling physicians’ medical decisions, or engaging in certain practices, such as splitting fees with physicians; and

	·	provisions of the Social Security Act (emanating from the Deficit Reduction Act of 2005 (the “DRA”)) that require entities that make or receive annual Medicaid payments of $5 million or more from a single Medicaid program to provide their employees, contractors and agents with written policies and employee handbook materials on federal and state false claims acts and related statutes, that establish a new Medicaid Integrity Program designed to enhance federal and state efforts to detect Medicaid fraud, waste, and abuse, and that increase financial incentives for both states and individuals to bring fraud and abuse claims against healthcare companies.

	•·	variations in our quarterly operating results,
	•·	changes in general economic conditions,
	•·	changes in market valuations of similar companies,
	•·	announcements by us or our competitors of significant acquisitions, strategic partnerships or joint ventures, or capital ~~commitments;~~commitments,
	·	poor reviews;
	·	loss of a major customer, partner, or joint venture participant; and
	•·	~~poor reviews.~~the addition or loss of key managerial and collaborative personnel.

	•·	that a broker or dealer approve a person’s account for transactions in penny stocks, and
	•·	the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

		In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:

	•·	obtain financial information and investment experience objectives of the person, and
	•·	make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

	•·	sets forth the basis on which the broker or dealer made the suitability determination and
	•·	that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

Period	High		Low
Fiscal Year 2020
First Quarter (July 1, 2019 – September 30, 2019)	$	0.1300	$	0.0070
Second Quarter (October 1, 2019 – December 31, 2019)	$	0.0490	$	0.0086
Third Quarter (January 1, 2020 – March 31, 2020)	$	0.0490	$	0.0230
Fourth Quarter (April 1, 2020 – June 30, 2020)	$	0.0800	$	0.0115

	June 30, 2020		June 30, 2019
Notes payable	$	215,323	$	215,323
Notes payable related parties	$	4,001,267	$	4,001,267
Receiver certificate	$	65,000	$	65,000

•·	We did not perform an effective risk assessment or monitor internal controls over financial reporting.

•·	There are insufficient written policies and procedures to ensure the correct application of accounting and financial reporting with respect to the current requirements of generally accepted accounting principles in the United States and SEC disclosure requirements.

•·	Limited segregation of duties and oversight of work performed as well as lack of compensating controls in the Company’s finance and accounting ~~functions due to the receivership.~~functions.

•·	The Company lacks sufficient in-house expertise and training in complex accounting principles and SEC reporting and disclosure requirements.

•·	The Company’s systems that impact financial information and disclosures have ineffective information technology controls.

•·	The Company lacks a system of tracking obligations to identify and file income tax and other tax reports on a timely basis.

Name	Age	Position
Justin Smith	41	Interim Chief Executive Officer, Interim Chief Financial Officer, Executive Chairman and Director
Jonathan Loutzenhiser	35	Executive Vice President and Director
Dr. Joseph Asuncion	59	Chief Medical Officer and Director
Dr. Charles Balaban	72	Director
Dr. Sadeem Mahmood	58	Chief of Surgery
Dr. Richard Muckerman	70	Vice President of Strategy and Business
Blake Moorman	40	Vice President of Operations
Dr. Richard F. Wittock	49	Vice President of Clinical Affairs

Name	Year	Salary ($)		Bonus ($)		All Other Compensation ($)			Total ($)
Robert Stevens	2019	$	-	$	-	$	8,838	⁽¹⁾	$	8,838
Receiver	2020	$	-	$	-	$	3,555	⁽²⁾	$	3,555

	•·	each person known by us to be the beneficial owner of more than 5% of our common stock;

	•·	each of our directors;

	•·	each of our named executive officers; and

	•·	our executive officers and directors as a group.

Name of Beneficial Owner:	Amount and Nature of Beneficial Ownership		Percent of Class
Directors and Executive Officers
Robert Stevens⁽¹⁾		-	*

More than 5% Holders
Next New Deal LLC⁽²⁾		38,199,918		30.00	%
Take Flight Equities Inc⁽³⁾		38,199,918		30.00	%
Thistle Investments LLC ⁽⁴⁾		38,199,918		30.00	%

Name of Beneficial Owner:	Amount and Nature of Beneficial Ownership⁽²⁾		Percent of Class⁽¹⁾
Directors and Executive Officers
Justin Smith ⁽³⁾		996,520		1.08
Dr. Charles Balaban⁽⁴⁾		22,539,450		24.48
Jonathan Loutzenhiser⁽⁵⁾		22,000,000		23.89
Dr. Joseph Asuncion⁽⁶⁾		539,450	*
Dr. Sadeem Mahmood⁽⁷⁾		0	*
Dr. Richard F. Wittock⁽⁸⁾		96,652	*
Dr. Richard Muckerman⁽⁹⁾		9,966	*
Blake Moorman⁽¹⁰⁾		0	*
Officers and Directors as a Group (8 persons)		46,185,038		50.16

More than 5% Holders
Jackson Hole Medical Advisors, Inc.⁽¹¹⁾		22,000,000		23.89
168 Capital Inc.⁽¹²⁾		9,249,130		10.05

(1)	BLS, Inc. is controlled by Charles Balaban, a Director of the Company

(2)	BOAM, Inc. is controlled by Charles Balaban

(3)	Healthcare Solutions DX, Inc. is controlled by Justin Smith, Chairman of the Company’s Board of Directors

(4)	JHMA, Inc. is controlled by Doug Millar, head of the Company’s Corporate Compliance and Regulatory Matters

(5)	Jonathan Loutzenhiser – is a Vice President of the Company.

	Balance Due		Balance Due
	9/30/2021		9/30/2020

BLS, Inc.	$	3,997,500	$	3,690,000
BOAM, Inc.		582,409		582,409
Healthcare Solutions DX, Inc.		1,302,151		1,161,239
JHMA, Inc.		4,114,490		3,748,329
Jonathan Loutzenhiser		3,608,590		3,241,429

Contents		Page

Report of ~~Current~~ Independent Registered Public Accounting Firm (PCAOB ID 5041)		F-1

~~Report of Former Independent Registered Public Accounting Firm~~Consolidated Balance Sheets on September 30, 2021, and 2020		F-2

~~Consolidated Balance Sheets at June 30, 2020, and 2019~~		~~F-3~~

Consolidated Statements of Operations for the Years Ended ~~June~~September 30, ~~2020,~~2021, and ~~2019~~2020		~~F-4~~F-3

Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended ~~June~~September 30, ~~2020,~~2021, and ~~2019~~2020		~~F-5~~F-4

Consolidated Statements of Cash Flows for the Years Ended ~~June~~September 30, ~~2020,~~2021, and ~~2019~~2020		~~F-6~~F-5

Notes to the Consolidated Financial Statements		~~F-7~~F-6

Healthcare Solutions Management Group, Inc.
CONSOLIDATED BALANCE SHEETS

	September 30,			September 30,
	2021			2020
ASSETS
Cash	$	659,194		$	841,349
Accounts receivable/other receivable		825,712			74,622
Prepaid expenses		0			60,666
Investments		89,823,346			83,087,469
Total current assets		91,308,252			84,064,105
Equipment		1,821,081			587,083
Total Assets	$	93,129,332		$	84,651,188

LIABILITIES & STOCKHOLDERS' DEFICIT

Current liabilities
Accounts payable	$	22,200		$	109,313
PPP loan		210,500			210,500
Notes payable		456,000			465,323
Receiver-certificate		0			65,000
Interest payable		0			33,093
Notes payable related party		13,786,051			13,447,615
Total current liabilities		14,474,751			14,330,844
Total liabilities		14,474,751			14,330,844
Stockholders' Equity
Common stock, par value $0.001, 1,400,000,000 shares authorized 11,072,440 and 1,107,244
shares issued and outstanding as of September 30, 2021, and September 30, 2020, respectively		11,072			1,107
Additional paid in capital		102,216,342			97,839,775
Accumulated other comprehensive income		5,598,328			(1,137,548	)
Retained earnings (deficit)		(29,171,161	)		(26,382,990	)
Total Stockholders' (Deficit)		78,654,581			70,320,344
Total Liabilities and Stockholders' (Equity)	$	93,129,332		$	84,651,188

The accompanying notes are an integral part of these consolidated financial statements.


F-2
~~BMKR, LLP~~ ~~Certified Public Accountants~~ ~~1200 Veterans Memorial Hwy., Suite 350~~ ~~Hauppauge, New York 11788~~	~~T 631 293-5000~~ ~~F 631 234-4272~~ ~~www.bmkr.com~~
		Table of Contents
~~Thomas G. Kober, CPA~~ ~~Alfred M. Rizzo, CPA~~ ~~Joseph Mortimer, CPA~~	~~Charles W. Blanchfield, CPA (Retired)~~ ~~Bruce A. Meyer, CPA (Retired)~~

Healthcare Solutions Management Group, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS


	Year			Year
	Ended			Ended
	September 30,			September 30,
	2021			2020
Revenue
Sales	$	8,566,284		$	3,524,334
Sales related party		682,500			0
Total revenue		9,248,784			3,524,334
Cost of goods sold		166,734			0
Cost of goods sold -related party		2,297,455			2,595,860
Gross profit		6,784,595			928,474

Operating Expenses:
Administrative expenses		3,491,623			1,648,341
Contractors expenses		203,722			573,706
Contractors expenses related party		5,743,637			1,730,574
Total operating expenses		9,438,982			3,952,621
(Loss) from operations		(2,654,387	)		(3,024,147	)
Other income (expense)
Interest income (expense), net		(133,785	)		(6,250	)
Income (loss) before provision for income taxes		(2,788,171	)		(3,030,397	)
Provision for income taxes		0			0
Net (Loss)	$	(2,788,171	)	$	(3,030,397	)

Basic and diluted earnings(loss) per common share	$	(0.49	)	$	(27.37	)

Weighted average number of shares outstanding		5,693,964			110,724

The accompanying notes are an integral part of these consolidated financial statements.